[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 517
1. Ogata H, Mizobuchi M, Koiwa F, Kinugasa E, Akizawa T: Clinical significance of parathyroid intervention on CKD-MBD management. NDT Plus; 2008 Aug;1(Suppl 3):iii9-iii13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of parathyroid intervention on CKD-MBD management.
  • Recently published 'Guidelines for the management of secondary hyperparathyroidism in chronic dialysis patients' by the Japanese Society for Dialysis Therapy advocate that percutaneous ethanol injection into enlarged glands, which has been considered as the only alternative to parathyroidectomy (PTx), should be indicated in patients with a single enlarged parathyroid gland (estimated volume >500 mm(3), or estimated major axis >10 mm), and that PTx should be recommended in patients with multiple enlarged glands.
  • Cinacalcet cannot achieve optimal control of chronic kidney disease-mineral bone disorder in all patients, and parathyroid intervention will be required in a considerable number of patients with refractory secondary hyperparathyroidism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25983977.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4421131
  •  go-up   go-down


2. Stillion JR, Ritt MG: Renal secondary hyperparathyroidism in dogs. Compend Contin Educ Vet; 2009 Jun;31(6):E8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The parathyroid glands secrete parathyroid hormone (PTH), which is important for maintaining calcium homeostasis.
  • Parathyroid gland hyperplasia and subsequent hyperparathyroidism can occur secondary to chronic renal failure in dogs, resulting in significant alterations in calcium metabolism.
  • [MeSH-major] Calcium / metabolism. Dog Diseases / diagnosis. Hyperparathyroidism, Secondary / veterinary. Parathyroid Hormone / secretion
  • [MeSH-minor] Animals. Dogs. Kidney Failure, Chronic / complications. Kidney Failure, Chronic / diagnosis. Kidney Failure, Chronic / veterinary. Prognosis

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19746344.001).
  • [ISSN] 1940-8315
  • [Journal-full-title] Compendium (Yardley, PA)
  • [ISO-abbreviation] Compend Contin Educ Vet
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone; SY7Q814VUP / Calcium
  •  go-up   go-down


3. Mun HC, Brennan SC, Delbridge L, Wilkinson M, Brown EM, Conigrave AD: Adenomatous human parathyroid cells exhibit impaired sensitivity to L-amino acids. J Clin Endocrinol Metab; 2009 Sep;94(9):3567-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatous human parathyroid cells exhibit impaired sensitivity to L-amino acids.
  • CONTEXT: Primary hyperparathyroidism, which occurs most commonly in patients with adenomatous disease of a single parathyroid gland, arises as a result of impaired extracellular Ca(2+) (Ca(2+)(o))-dependent feedback on PTH secretion, a process mediated by the calcium-sensing receptor (CaR).
  • OBJECTIVE: Because the Ca(2+)(o) sensitivity of the CaR is positively modulated by L-amino acids, we decided to investigate whether the impaired feedback of PTH secretion in adenomatous parathyroid cells might arise from decreased sensitivity to L-amino acids.
  • DESIGN: Samples of normal and adenomatous human parathyroid cells were prepared by collagenase treatment and then exposed in vitro to various concentrations of Ca(2+)(o) or the CaR-active amino acid, L-phenylalanine (L-Phe).
  • SETTING AND PATIENTS: Excess normal parathyroid tissue was obtained from parathyroid autotransplants at the time of thyroid surgery.
  • Samples of adenomatous tissue were obtained from histologically confirmed parathyroid adenomas.
  • RESULTS: Parathyroid adenomas exhibited reduced sensitivity to the CaR-active amino acid L-Phe, which affected both Ca(2+)(o)-dependent PTH secretion and Ca(2+)(o)-dependent intracellular Ca(2+) mobilization as a measure of CaR-dependent signaling in parathyroid cells.
  • CONCLUSIONS: Impaired L-amino acid sensing by calcium-sensing receptors in adenomatous parathyroid cells contributes to the loss of feedback control of PTH secretion in primary hyperparathyroidism.
  • [MeSH-major] Adenoma / secretion. Amino Acids / pharmacology. Parathyroid Neoplasms / secretion
  • [MeSH-minor] Calcium / metabolism. Feedback, Physiological. Humans. Parathyroid Glands / metabolism. Parathyroid Hormone / secretion. Phenylalanine / pharmacology. Receptors, Calcium-Sensing / physiology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 May 24;277(21):18908-13 [11880385.001]
  • [Cites] Physiol Rev. 2001 Jan;81(1):239-297 [11152759.001]
  • [Cites] Eur J Clin Nutr. 2002 Nov;56(11):1072-80 [12428172.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38151-9 [15234970.001]
  • [Cites] J Clin Endocrinol Metab. 1978 Feb;46(2):267-75 [750604.001]
  • [Cites] Am J Physiol. 1989 Dec;257(6 Pt 1):G982-9 [2610264.001]
  • [Cites] J Endocrinol. 1996 Apr;149(1):135-44 [8676046.001]
  • [Cites] Surgery. 1998 Dec;124(6):1094-8; discussion 1098-9 [9854589.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):51739-44 [15579475.001]
  • [Cites] Surgery. 2005 Dec;138(6):1111-20; discussion 1120 [16360398.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Nov;291(5):G753-61 [17030896.001]
  • [Cites] Trends Endocrinol Metab. 2006 Dec;17(10):398-407 [17085057.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4814-9 [10781086.001]
  • [Cites] Endocrinology. 2000 Nov;141(11):4156-63 [11089548.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4789-94 [11134144.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):33736-41 [12114500.001]
  • (PMID = 19567535.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Parathyroid Hormone; 0 / Receptors, Calcium-Sensing; 47E5O17Y3R / Phenylalanine; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2741716
  •  go-up   go-down


Advertisement
4. Solorzano CC, Carneiro-Pla DM, Irvin GL 3rd: Surgeon-performed ultrasonography as the initial and only localizing study in sporadic primary hyperparathyroidism. J Am Coll Surg; 2006 Jan;202(1):18-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: With a secure diagnosis of hyperparathyroidism, preoperative localization of abnormal glands is the initial step toward limited parathyroidectomy.
  • STUDY DESIGN: Two hundred twenty-six patients underwent preoperative SUS and Sestamibi scans before limited parathyroidectomy guided by quick intraoperative parathyroid hormone assay.
  • In 53 patients, SUS showed no parathyroid gland (n = 32), did not recognize multiglandular disease (n = 5), and showed an incorrect location of the abnormal gland (n = 16).
  • With use of quick intraoperative parathyroid hormone assay, successful parathyroidectomy was accomplished in 223 of 226 (99%), unilateral exploration in 88%, and overnight stay avoided in 78% of patients.

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16377493.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


5. Bonczynski J: Primary hyperparathyroidism in dogs and cats. Clin Tech Small Anim Pract; 2007 May;22(2):70-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common cause of primary hyperparathyroidism in dogs and cats is a solitary adenoma involving an extracapsular parathyroid gland.
  • The prognosis is excellent if the affected parathyroid gland is removed.
  • [MeSH-major] Cat Diseases / diagnosis. Cat Diseases / surgery. Dog Diseases / diagnosis. Dog Diseases / surgery. Hyperparathyroidism, Primary / veterinary

  • SciCrunch. OMIA - Online Mendelian Inheritance in Animals: Data: Gene Expression .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591292.001).
  • [ISSN] 1096-2867
  • [Journal-full-title] Clinical techniques in small animal practice
  • [ISO-abbreviation] Clin Tech Small Anim Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


6. Tiet TD, Hopyan S, Nadesan P, Gokgoz N, Poon R, Lin AC, Yan T, Andrulis IL, Alman BA, Wunder JS: Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am J Pathol; 2006 Jan;168(1):321-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation.
  • Chondrosarcoma is a malignant cartilage tumor that may arise from benign precursor lesions, such as enchondromas.
  • Treatment with parathyroid hormone-related protein down-regulated Indian Hedgehog (IHH) expression in normal growth plates but not in chondrosarcoma or enchondroma organ cultures.
  • Treatment with triparanol, an inhibitor of Hedgehog signaling, resulted in a 60% decrease in tumor volume, a 30% decrease in cellularity, and a 20% reduction in proliferation rate.
  • These results show that Hedgehog signaling is active in chondrosarcoma and benign cartilage tumors and regulates tumor cell proliferation.
  • Our data raise the intriguing possibility that Hedgehog blockade could serve as an effective treatment for chondrosarcoma, a tumor for which there are currently no universally effective nonsurgical management options.
  • [MeSH-major] Bone Neoplasms / metabolism. Cell Proliferation. Chondrosarcoma / metabolism. Parathyroid Hormone-Related Protein / metabolism. Signal Transduction / physiology. Trans-Activators / metabolism

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endocrinol. 1996 Sep;150(3):359-68 [8882154.001]
  • [Cites] Cell. 1996 Nov 15;87(4):661-73 [8929535.001]
  • [Cites] J Endocrinol. 1997 Sep;154 Suppl:S39-45 [9379136.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13689-94 [9391087.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):783-8 [9989829.001]
  • [Cites] Arch Biochem Biophys. 1959 Nov;85:250-63 [13801562.001]
  • [Cites] J Orthop Res. 1999 Sep;17(5):633-8 [10569470.001]
  • [Cites] Curr Biol. 1999 Nov 18;9(22):1319-22 [10574767.001]
  • [Cites] Dev Dyn. 2000 Jul;218(3):452-64 [10878610.001]
  • [Cites] Nature. 2000 Aug 31;406(6799):944-5 [10984033.001]
  • [Cites] Lab Invest. 2000 Dec;80(12):1925-34 [11140704.001]
  • [Cites] Endocrinology. 2001 Mar;142(3):1260-8 [11181543.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):295-304 [11160153.001]
  • [Cites] Oncogene. 2001 Jan 25;20(4):451-60 [11313976.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • [Cites] Mech Dev. 2001 Aug;106(1-2):107-17 [11472839.001]
  • [Cites] Mol Biol Cell. 2001 Dec;12(12):3852-63 [11739785.001]
  • [Cites] Development. 2001 Dec;128(24):5099-108 [11748145.001]
  • [Cites] J Bone Joint Surg Br. 2002 Jan;84(1):93-9 [11837841.001]
  • [Cites] Nat Genet. 2002 Mar;30(3):306-10 [11850620.001]
  • [Cites] Pathology. 2002 Apr;34(2):133-7 [12009094.001]
  • [Cites] Development. 2002 Jun;129(12):2977-86 [12050144.001]
  • [Cites] J Cell Sci. 2002 Jul 15;115(Pt 14):3015-25 [12082161.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403):198-204 [12360027.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4616-21 [12679522.001]
  • [Cites] Hum Mol Genet. 2003 May 15;12(10):1187-98 [12719383.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] J Pathol. 2004 Jan;202(1):113-20 [14694528.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):229-40 [15380514.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] J Bone Joint Surg Am. 1987 Feb;69(2):269-74 [3805090.001]
  • [Cites] Am J Vet Res. 1993 Jul;54(7):1116-21 [8368608.001]
  • [Cites] J Cell Biol. 1994 Sep;126(6):1611-23 [8089190.001]
  • [Cites] Dev Biol. 1996 Apr 10;175(1):166-76 [8608863.001]
  • [Cites] Science. 1996 Aug 2;273(5275):613-22 [8662546.001]
  • [Cites] Science. 1996 Aug 2;273(5275):663-6 [8662561.001]
  • [Cites] Arch Biochem Biophys. 1959 Nov;85:245-9 [13801564.001]
  • [Cites] Hum Mutat. 2004 Dec;24(6):466-73 [15523647.001]
  • [Cites] J Pathol. 2005 Mar;205(4):476-82 [15685701.001]
  • [Cites] Endocrinology. 1996 Nov;137(11):5055-67 [8895380.001]
  • (PMID = 16400033.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gli protein; 0 / Hedgehog Proteins; 0 / Hypolipidemic Agents; 0 / Oncogene Proteins; 0 / Parathyroid Hormone-Related Protein; 0 / Receptors, Cell Surface; 0 / Trans-Activators; 0 / Transcription Factors; 0 / patched receptors; 63S8C3RXGS / Triparanol
  • [Other-IDs] NLM/ PMC1592680
  •  go-up   go-down


7. Imachi H, Murao K, Kontani K, Yokomise H, Miyai Y, Yamamoto Y, Kushida Y, Haba R, Ishida T: Ectopic mediastinal parathyroid adenoma: a cause of acute pancreatitis. Endocrine; 2009 Oct;36(2):194-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic mediastinal parathyroid adenoma: a cause of acute pancreatitis.
  • After the episode of acute pancreatitis subsided, laboratory investigation revealed increased serum calcium (12.0 mg/dl), decreased serum phosphorus (2.7 mg/dl), and increased serum parathyroid hormone (intact) levels (131 pg/ml).
  • A computed tomography (CT) scan of the neck did not reveal any mass lesions in the parathyroid gland.
  • However, (99m)Tc sestamibi scintigraphy revealed that there was one functioning parathyroid gland in the upper mediastinum.
  • Combined (99m)Tc sestamibi scintigraphy and CT scan confirmed the diagnosis of primary hyperparathyroidism in the mediastinum.
  • Microscopic examination revealed the presence of a parathyroid adenoma (1.3 x 0.4 cm(2)) adjacent to the atrophic parathyroid gland in right thymus gland.
  • We report the case of a patient diagnosed with primary hyperparathyroidism due to an ectopic mediastinal parathyroid adenoma.
  • An ectopic mediastinal parathyroid adenoma may manifest as an episode of acute pancreatitis.
  • [MeSH-major] Adenoma / complications. Choristoma. Mediastinal Diseases / complications. Pancreatitis / etiology. Parathyroid Glands. Parathyroid Neoplasms / complications
  • [MeSH-minor] Adult. Humans. Hyperparathyroidism, Primary / diagnosis. Hyperparathyroidism, Primary / etiology. Male

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2002 Sep;195(3):364-71 [12229945.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):740-4 [16916398.001]
  • [Cites] Indian J Gastroenterol. 2003 Nov-Dec;22(6):224-5 [15030035.001]
  • [Cites] J Pediatr Endocrinol Metab. 2008 Dec;21(12):1191-4 [19189694.001]
  • [Cites] J Nucl Med. 2008 Nov;49(11):1813-8 [18927330.001]
  • [Cites] Alcohol. 2008 Nov;42(7):565-73 [18774672.001]
  • [Cites] Semin Nucl Med. 2005 Oct;35(4):266-76 [16150247.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Jun;23(6):959-64 [17683498.001]
  • [Cites] World J Surg. 2005 Apr;29(4):491-4 [15770373.001]
  • [Cites] Rev Esp Enferm Dig. 2009 Jan;101(1):65-9 [19335036.001]
  • [Cites] Radiographics. 1999 May-Jun;19(3):601-14; discussion 615-6 [10336191.001]
  • [Cites] Surgery. 2004 Dec;136(6):1199-204 [15657576.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1746-51 [15103001.001]
  • [Cites] Am J Surg. 2008 Jun;195(6):799-802 [18436184.001]
  • [Cites] Aust N Z J Surg. 1996 Feb;66(2):85-7 [8602820.001]
  • [Cites] Aust N Z J Surg. 1998 Feb;68(2):117-9 [9494002.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jun;94(6):2115-8 [19318456.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Sep;23(9):1339-48 [18853993.001]
  • [Cites] Nucl Med Commun. 2005 Jul;26(7):633-8 [15942484.001]
  • (PMID = 19598003.001).
  • [ISSN] 1559-0100
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Massaro F, Dolcino M, Degrandi R, Ferone D, Mussap M, Minuto F, Giusti M: Calcitonin assay in wash-out fluid after fine-needle aspiration biopsy in patients with a thyroid nodule and border-line value of the hormone. J Endocrinol Invest; 2009 Apr;32(4):308-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Assaying calcitonin (CT) in the wash-out fluid from fine-needle aspiration biopsies (CT-FNAB) could be useful in the diagnosis of medullary thyroid carcinoma (MTC).
  • In 4 patients, CT-FNAB values were higher than the highest values found in our negative controls (30 ng/l), but cytology results were compatible with a benign thyroid lesion and pentagastrin testing was negative.
  • Our experience suggests that CT-FNAB does not have the same importance as that reported in the literature for thyroglobulin and PTH assay in wash-out fluid after FNAB in malignant thyroid and hyperfunctioning parathyroid lesions.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Calcitonin / metabolism. Carcinoma, Medullary / pathology. Thyroid Nodule / pathology
  • [MeSH-minor] Adult. Aged. Biological Assay. Biopsy, Fine-Needle. Body Fluids / metabolism. Female. Humans. Lymph Nodes. Lymphatic Metastasis. Male. Middle Aged. Retrospective Studies. Thyroid Gland / metabolism

  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Minerva Endocrinol. 2006 Jun;31(2):159-72 [16682939.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jun;92(6):2115-8 [17405835.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1364-9 [16434461.001]
  • [Cites] Cytojournal. 2006 Mar 28;3:6 [16569241.001]
  • [Cites] Radiology. 1988 Sep;168(3):769-72 [3043550.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jun;74(6):1401-4 [1592886.001]
  • [Cites] Histopathology. 1992 Nov;21(5):469-74 [1452130.001]
  • [Cites] Thyroid. 2006 Feb;16(2):109-42 [16420177.001]
  • [Cites] Thyroid. 2001 Jan;11(1):73-80 [11272100.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Apr;78(4):826-9 [8157706.001]
  • [Cites] Eur J Endocrinol. 2006 Jun;154(6):787-803 [16728537.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):515-9 [14764755.001]
  • [Cites] Ann Endocrinol (Paris). 1996;57(1):15-21 [8734284.001]
  • [Cites] J Surg Oncol. 2005 Jul 1;91(1):56-60 [15999359.001]
  • [Cites] Thyroid. 2007 Jul;17(7):635-8 [17696833.001]
  • [Cites] G Chir. 2007 Oct;28(10):385-9 [17915054.001]
  • [Cites] Eur J Endocrinol. 1998 Jan;138(1):41-6 [9461314.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Feb;92(2):450-5 [17119000.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):163-8 [14715844.001]
  • [Cites] Eur J Surg Oncol. 2005 Sep;31(7):774-7 [15925476.001]
  • [Cites] Thyroid. 1999 Feb;9(2):105-11 [10090308.001]
  • [Cites] Acta Cytol. 2005 Sep-Oct;49(5):477-82 [16334022.001]
  • [Cites] Endocr Pract. 2007 Jul-Aug;13(4):333-7 [17669707.001]
  • (PMID = 19636196.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9007-12-9 / Calcitonin
  •  go-up   go-down


9. Khan MK, Taous A, Sultana SZ, Sharif A, Hossain MM, Mostafa G, Hussain MA, Azim MA, Siddique MA: Neck swelling with renal stone. Mymensingh Med J; 2010 Oct;19(4):622-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Number of parathyroid glands and their ectopic locations in individuals are the problem of its management.
  • Parathyroid adenoma or hyperplasia may be a part of Multiple Endocrine neoplasia type II.
  • After search, hypercalcaemia, bilateral renal stone, raised parathormone level and enlarged one parathyroid gland in lower pole of left thyroid lobe was identified.
  • Clinically it was diagnosed as parathyroid adenoma which was proved histologically after surgical excision.
  • Many controversies still exist regarding the treatment policy of parathyroid adenoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20956910.001).
  • [ISSN] 1022-4742
  • [Journal-full-title] Mymensingh medical journal : MMJ
  • [ISO-abbreviation] Mymensingh Med J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Bangladesh
  •  go-up   go-down


10. Kalinichenko OV, Myshunina TM, Tron'ko MD: [B-, H- and L-cathepsin-like activity in blood plasma of patients with diseases of the thyroid, parathyroid and adrenal glands]. Ukr Biokhim Zh (1999); 2010 Mar-Apr;82(2):53-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [B-, H- and L-cathepsin-like activity in blood plasma of patients with diseases of the thyroid, parathyroid and adrenal glands].
  • B-, H- and L-catepsine-like activity regarding Na-benzoyl-D,L-arginine-4-nitroanilide, L-leucine-4-nitroanilide and azocasein was studied in the blood plasma of patients with different diseases of thyroid, parathyroid and adrenal glands.
  • In diaseses of the adrenal glands the changes in the B- and L-catepsine-like activity were only shown in the blood plasma of patients with cerebral layer tumors but not the gland cortex: B-catepsine-like activity increased in the blood plasma of patients with benign or malignant tumors, and L-catepsine-like activity decreased under benign tumor from chromaffin tissue.
  • The established picture of changes in enzymatic activity in the blood plasma of patients does not allow to think that the determination of blood B- and L- catepsine-like activity can be recommended for obtaining additional information at diagnosis thyroid diseases.
  • [MeSH-major] Adrenal Gland Diseases / blood. Cathepsin B / blood. Cathepsin H / blood. Cathepsin L / blood. Parathyroid Diseases / blood. Thyroid Diseases / blood

  • Genetic Alliance. consumer health - Adrenal Diseases.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.
  • MedlinePlus Health Information. consumer health - Parathyroid Disorders.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20684245.001).
  • [Journal-full-title] Ukraïnsʹkyĭ biokhimichnyĭ z︠h︡urnal (1999 )
  • [ISO-abbreviation] Ukr Biokhim Zh (1999)
  • [Language] ukr
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] EC 3.4.22.1 / CTSB protein, human; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / CTSL1 protein, human; EC 3.4.22.15 / Cathepsin L; EC 3.4.22.16 / CTSH protein, human; EC 3.4.22.16 / Cathepsin H
  •  go-up   go-down


11. Gómez Marqués G, Obrador Mulet A, Vilar Gimeno A, Pascual Felip MJ, Alarcón Zurita A, Molina Guasch M, Uriol Rivera M, Munar Vila MA, Losada González P: Treatment with cinacalcet of secondary hyperparathyroidism after renal transplantation. Transplant Proc; 2009 Jul-Aug;41(6):2139-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Calcimimetics inhibit parathyroid hormone (PTH) secretion by modulating the calcium-sensing receptor in the parathyroid gland.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19715856.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Naphthalenes; 1406-16-2 / Vitamin D; 1K860WSG25 / Cinacalcet Hydrochloride; 27YLU75U4W / Phosphorus; FXC9231JVH / Calcitriol
  •  go-up   go-down


12. Brandi ML: Parathyroid gland: Hyperparathyroidism in MEN1 syndrome: time to operate? Nat Rev Endocrinol; 2010 Nov;6(11):604-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parathyroid gland: Hyperparathyroidism in MEN1 syndrome: time to operate?
  • [MeSH-major] Hyperparathyroidism / complications. Hyperparathyroidism / surgery. Multiple Endocrine Neoplasia Type 1 / complications
  • [MeSH-minor] Adult. Bone Diseases / diagnosis. Bone Diseases / etiology. Female. Humans. Kidney Diseases / diagnosis. Kidney Diseases / etiology. Middle Aged

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20962866.001).
  • [ISSN] 1759-5037
  • [Journal-full-title] Nature reviews. Endocrinology
  • [ISO-abbreviation] Nat Rev Endocrinol
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] England
  •  go-up   go-down


13. Marcheix B, Brouchet L, Berjaud J, Dahan M: Recurrent hyperparathyroidism: A sixth mediastinal parathyroid gland. Eur J Cardiothorac Surg; 2006 Nov;30(5):808-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent hyperparathyroidism: A sixth mediastinal parathyroid gland.
  • She underwent first a subtotal resection of the parathyroid glands associated with subtotal thyroidectomy in the setting of primary hyperparathyroidism and multi nodular thyroid.
  • Pathologic findings were consistent with hyperplasia and demonstrated a fifth parathyroid gland in the thyroid.
  • Two years later, the patient presented recurrent hyperparathyroidism associated with terminal renal insufficiency, fusion of Sesta Mibi scintigraphy and CT scan demonstrated a sixth mediastinal parathyroid gland in the aorto pulmonary window.
  • Pathologic findings demonstrated a parathyroid adenoma.
  • [MeSH-major] Choristoma / complications. Hyperparathyroidism / etiology. Mediastinal Diseases / complications. Parathyroid Glands
  • [MeSH-minor] Adenoma / complications. Aged. Female. Humans. Parathyroid Neoplasms / complications. Parathyroidectomy. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979898.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Masatsugu T, Yamashita H, Noguchi S, Nishii R, Watanabe S, Uchino S, Kuroki S, Tanaka M: Significant clinical differences in primary hyperparathyroidism between patients with and those without concomitant thyroid disease. Surg Today; 2005;35(5):351-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: We evaluated the differences in diagnosis and treatment for primary hyperparathyroidism (pHPT) in patients with and those without concomitant thyroid disease.
  • METHODS: One hundred and ten patients with pHPT underwent parathyroid localization and thyroid examination by ultrasonography (US) and sestamibi scintigraphy (MIBI).
  • The clinical and biochemical findings, parathyroid localization, and operations performed were compared in 49 patients without thyroid disease and 61 patients with thyroid disease.
  • The pathologic parathyroid gland was identified significantly more often in patients without concomitant thyroid disease than in those with concomitant thyroid disease both by US and MIBI (P < 0.05).
  • Thyroid disease concomitant with pHPT influenced parathyroid localization as well as the indication for minimally invasive parathyroidectomy.
  • [MeSH-major] Hyperparathyroidism / complications. Hyperparathyroidism / diagnosis. Hyperparathyroidism / surgery. Thyroid Diseases / complications

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15864415.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


15. Terawaki H, Nakano H, Takeguchi F, Hasegawa T, Nakayama M, Okazaki M, Hosoya T: Regression of parathyroid gland swelling by treatment with cinacalcet. Nephrol Dial Transplant; 2009 Feb;24(2):690-1; author reply 691-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of parathyroid gland swelling by treatment with cinacalcet.
  • [MeSH-minor] Calcium / metabolism. Cinacalcet Hydrochloride. Female. Humans. Hyperplasia. Kidney Failure, Chronic / complications. Kidney Failure, Chronic / therapy. Middle Aged. Parathyroid Glands / drug effects. Parathyroid Glands / pathology. Renal Dialysis / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Nephrol Dial Transplant. 2008 Jan;23(1):328-35 [17717030.001]
  • (PMID = 18987257.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Naphthalenes; 1K860WSG25 / Cinacalcet Hydrochloride; SY7Q814VUP / Calcium
  •  go-up   go-down


16. Su DH, Liao KM, Chang YC, Tsai KS: Secondary hyperparathyroidism as a palpable intrathyroid parathyroid gland in a patient with hypophosphatemic osteomalacia. J Bone Miner Metab; 2006;24(2):114-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary hyperparathyroidism as a palpable intrathyroid parathyroid gland in a patient with hypophosphatemic osteomalacia.
  • An intrathyroid parathyroid gland was confirmed through partial thyroidectomy and parathyroidectomy.
  • Renal phosphate wasting decreased strongly, and serum parathyroid hormone was in the normal range after the operation.
  • [MeSH-major] Hyperparathyroidism, Secondary / diagnosis. Osteomalacia / complications. Parathyroid Glands / pathology
  • [MeSH-minor] Female. Humans. Hypophosphatemia / pathology. Kidney Tubules / pathology. Middle Aged. Parathyroid Hormone / blood. Phosphates / chemistry. Phosphates / therapeutic use. Thyroid Gland / pathology

  • Genetic Alliance. consumer health - Osteomalacia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1987 Nov;36(3):198-205 [3682838.001]
  • [Cites] J Bone Miner Res. 2003 Jul;18(7):1227-34 [12854832.001]
  • [Cites] Bone. 2000 Sep;27(3):333-8 [10962341.001]
  • [Cites] J Am Soc Nephrol. 1992 Jun;2(12):1649-65 [1498272.001]
  • [Cites] Am J Med. 1987 Aug;83(2):350-4 [3303928.001]
  • [Cites] Br J Rheumatol. 1996 Jun;35(6):598-600 [8670586.001]
  • [Cites] Am J Med. 1985 Apr;78(4):669-73 [2984933.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Dec;75(6):1514-8 [1464657.001]
  • [Cites] J Endocrinol Invest. 2000 Apr;23(4):263-7 [10853715.001]
  • [Cites] Surgery. 1984 Jan;95(1):14-21 [6691181.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Feb;42(2):199-203 [7704964.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1705-8 [12711747.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jun;78(6):1378-83 [8200940.001]
  • [Cites] J Laryngol Otol. 1998 Apr;112(4):389-92 [9659507.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Feb;42(2):205-6 [7704965.001]
  • [Cites] Clin Nucl Med. 2002 Aug;27(8):582-3 [12170004.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1656-63 [12711740.001]
  • [Cites] Postgrad Med J. 1994 Aug;70(826):595-6 [7937459.001]
  • [Cites] J Clin Invest. 1995 Jul;96(1):327-33 [7615802.001]
  • [Cites] Pediatr Nephrol. 1999 Sep;13(7):607-11 [10460513.001]
  • [Cites] J Pathol. 1992 Jun;167(2):181-5 [1378890.001]
  • [Cites] Surgery. 1987 Jun;101(6):649-60 [3589961.001]
  • (PMID = 16502117.001).
  • [ISSN] 0914-8779
  • [Journal-full-title] Journal of bone and mineral metabolism
  • [ISO-abbreviation] J. Bone Miner. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 0 / Phosphates
  •  go-up   go-down


17. Gingalewski CA, Newman KD: Seminars: controversies in the management of pediatric thyroid malignancy. J Surg Oncol; 2006 Dec 15;94(8):748-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It often presents at advanced stages, yet behaves in a benign manner, when compared to its adult counterpart.
  • The best operative and adjuvant strategy for these children can only be determined when a better understanding of the tumor cell biology and genetics of this cancer is known.
  • [MeSH-minor] Adenoma / genetics. Adult. Carcinoma, Papillary. Carcinoma, Papillary, Follicular / secondary. Carcinoma, Papillary, Follicular / surgery. Child. Combined Modality Therapy. Disease-Free Survival. Humans. Hypoparathyroidism / etiology. Lymph Node Excision. Monitoring, Intraoperative. Mutation. Parathyroid Hormone / blood. Postoperative Complications. Proto-Oncogene Proteins c-ret / genetics. Recurrent Laryngeal Nerve Injuries. Retrospective Studies

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131405.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Parathyroid Hormone; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret
  • [Number-of-references] 15
  •  go-up   go-down


18. Hostutler RA, DiBartola SP, Chew DJ, Nagode LA, Schenck PA, Rajala-Schultz PJ, Drost WT: Comparison of the effects of daily and intermittent-dose calcitriol on serum parathyroid hormone and ionized calcium concentrations in normal cats and cats with chronic renal failure. J Vet Intern Med; 2006 Nov-Dec;20(6):1307-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the effects of daily and intermittent-dose calcitriol on serum parathyroid hormone and ionized calcium concentrations in normal cats and cats with chronic renal failure.
  • Early treatment of patients with chronic renal failure with calcitriol may be indicated because once established, parathyroid gland hyperplasia does not readily resolve with therapy.
  • HYPOTHESIS: Daily and intermittent dosing of calcitriol will decrease plasma parathyroid hormone concentration in normal cats and cats with chronic renal failure without causing ionized hypercalcemia.
  • Before each phase, calcitriol, parathyroid hormone, and ionized calcium concentrations were measured.
  • On the last day of both phases, calcitriol, parathyroid hormone, and ionized calcium concentrations were measured 0, 2, 4, and 6 hours after calcitriol administration.
  • RESULTS: Overall, serum parathyroid hormone concentrations were significantly higher in cats with chronic renal failure than in normal cats (P = .022), but serum parathyroid hormone concentrations for both normal cats and cats with chronic renal failure were not significantly different before and after 14 days of treatment with calcitriol, regardless of whether calcitriol was administered daily or intermittently.
  • CONCLUSIONS AND CLINICAL IMPORTANCE: At the dosages used, calcitriol treatment did not result in significant differences in serum parathyroid hormone concentrations before and after treatment in both normal cats and cats with chronic renal failure.

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17186842.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channel Agonists; 0 / Parathyroid Hormone; FXC9231JVH / Calcitriol; SY7Q814VUP / Calcium
  •  go-up   go-down


19. Yang YX: Proton pump inhibitor therapy and osteoporosis. Curr Drug Saf; 2008 Sep;3(3):204-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specifically, inhibition of the osteoclastic proton pumps may reduce bone resorption, while profound acid suppression could potentially hamper intestinal calcium absorption, and secondary hypergastrinemia may enhance bone resorption through the induction of parathyroid gland hyperplasia.

  • Genetic Alliance. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Fractures.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18691003.001).
  • [ISSN] 1574-8863
  • [Journal-full-title] Current drug safety
  • [ISO-abbreviation] Curr Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors; SY7Q814VUP / Calcium
  • [Number-of-references] 51
  •  go-up   go-down


20. Tanaka M, Ito K, Matsushita K, Matsushita K, Tominaga Y, Matsuoka S, Ueki T, Goto N, Sato T, Katayama A, Haba T, Uchida K: [Usefulness of power Doppler ultrasonography for the diagnosis of autoinfarction of parathyroid gland in secondary hyperparathyroidism]. Clin Calcium; 2005 Sep;15 Suppl 1:46-9; discussion 49-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Usefulness of power Doppler ultrasonography for the diagnosis of autoinfarction of parathyroid gland in secondary hyperparathyroidism].
  • Spontaneous remission due to parathyroid infarction of secondary hyperparathyroidism is rare compared with that of primary hyperparathyroidism, probably because several glands are enlarged in secondary hyperparathyroidism.
  • Lately, neck ultrasound examination has become a more beneficial and specific method for the diagnosis of enlarged parathyroid glands in contrast to classic diagnostic techniques such as computed tomography (CT), magnetic resonance imaging (MRI) and scintigraphy.
  • However, the diagnosis of parathyroid infarction reported in previous studies was often based on CT, MRI and scintigraphy findings and there are few studies that reported such diagnosis by urgent power Doppler ultrasonography of the neck.
  • Here we present a hemodialysis patient with autoinfarction of the left parathyroid gland diagnosed by urgent power Doppler ultrasonography of the neck.
  • [MeSH-major] Hyperparathyroidism, Secondary / ultrasonography. Infarction / ultrasonography. Parathyroid Glands / blood supply. Parathyroid Glands / ultrasonography. Ultrasonography, Doppler

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Calcium. 2006 Feb;16(2):149-52
  • (PMID = 16272629.001).
  • [ISSN] 0917-5857
  • [Journal-full-title] Clinical calcium
  • [ISO-abbreviation] Clin Calcium
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, Howell VM, Marsh DJ: Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol; 2006 Sep;30(9):1140-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
  • Parathyroid carcinoma is notoriously difficult to diagnose with confidence in borderline cases.
  • Commonly there is a long lag time between diagnosis and clinical evidence of malignant behavior even in histopathologically straightforward lesions.
  • There is therefore a need for a novel adjunctive marker to assist in the diagnosis of carcinoma.
  • Parafibromin is the protein encoded by the putative tumor suppressor gene HRPT2.
  • Mutations predicted to inactivate parafibromin were first detected in the germline of patients with hyperparathyroidism-jaw tumor (HPT-JT) syndrome.
  • We performed immunohistochemistry for parafibromin on 115 parathyroid tissues comprising 4 HPT-JT-related tumors (3 adenomas and 1 carcinoma), 11 sporadic parathyroid carcinomas, 79 sporadic adenomas, 3 multiple endocrine neoplasia 2A-related adenomas, 2 sporadic primary hyperplasias, 2 multiple endocrine neoplasia (MEN)-1-related hyperplasias, 6 secondary hyperplasias, 4 tertiary hyperplasias, and 4 normal parathyroid glands.
  • There was complete absence of nuclear staining in 3 of 4 (75%) HPT-JT-related tumors and 8 of 11 (73%) sporadic parathyroid carcinomas and focal weak staining in 1 of 4 HPT-JT tumors and 2 of 11 sporadic parathyroid carcinomas.
  • Only 1 parathyroid carcinoma exhibited diffuse strong nuclear expression of parafibromin.
  • In contrast, 98 of 100 non-HPT-JT-related benign parathyroids showed diffuse strong nuclear positivity and 2 of 100 showed weak positive staining.
  • We conclude that, in the correct clinical and pathologic context, complete absence of nuclear staining for parafibromin is diagnostic of parathyroid carcinoma or an HPT-JT-related tumor.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Hyperparathyroidism / complications. Jaw Neoplasms / complications. Parathyroid Glands / pathology. Parathyroid Neoplasms / diagnosis. Tumor Suppressor Proteins / analysis
  • [MeSH-minor] Cell Nucleus / chemistry. Humans. Hyperplasia. Immunohistochemistry. Multiple Endocrine Neoplasia / chemistry. Syndrome

  • Genetic Alliance. consumer health - Hyperparathyroidism-jaw tumor syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16931959.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDC73 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


22. Adam MA, Untch BR, Olson JA Jr: Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics. Oncologist; 2010;15(1):61-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics.
  • Parathyroid carcinoma is an indolent but ultimately life-threatening malignancy.
  • Due to the lack of definitive diagnostic markers and overlapping clinical features of benign primary hyperparathyroidism (PHPT), this disease is often misdiagnosed as parathyroid adenoma.
  • Owing to the rarity of the disease, little is known about the molecular pathogenesis of parathyroid carcinoma.
  • Here, we review the literature to present current understanding of the disease and provide new information on gene expression and use of intraoperative parathyroid hormone (PTH) monitoring in the surgical management of this rare malignancy.
  • Specifically, using microarray transcriptome analysis of an unequivocal case of parathyroid carcinoma and a biopsy from the same patient's normal parathyroid gland, we identify APP, CDH1, KCNJ16, and UCHL1 as differentially expressed genes in parathyroid carcinoma.
  • Further, using case records from four cases of unequivocal parathyroid carcinoma, we compared intraoperative PTH kinetics of these patients to 475 patients with benign PHPT, and show that intraoperative PTH monitoring is accurate in predicting postoperative normocalcemia in initial en bloc operations for parathyroid carcinoma.
  • [MeSH-major] Intraoperative Care. Monitoring, Physiologic. Parathyroid Hormone / blood. Parathyroid Neoplasms / genetics. Parathyroid Neoplasms / therapy
  • [MeSH-minor] Biopsy. Cinacalcet Hydrochloride. Diagnostic Imaging. Gene Expression. Humans. Hypercalcemia / drug therapy. Hypercalcemia / etiology. Hyperparathyroidism / etiology. Immunohistochemistry. Mutation. Naphthalenes / therapeutic use. Parathyroidectomy. Prognosis. Risk Factors. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17420-5 [18987311.001]
  • [Cites] Surgery. 2008 Dec;144(6):949-55; discussion 954-5 [19041002.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Feb;94(2):434-41 [19017757.001]
  • [Cites] J Bone Miner Metab. 2009;27(2):224-33 [19194773.001]
  • [Cites] Am J Otolaryngol. 2009 Jul-Aug;30(4):277-80 [19563942.001]
  • [Cites] Langenbecks Arch Surg. 2006 Nov;391(6):623-6 [17021789.001]
  • [Cites] Cancer. 2007 May 1;109(9):1736-41 [17372919.001]
  • [Cites] J Endocrinol Invest. 2000 Apr;23(4):255-7 [10853713.001]
  • [Cites] Surg Oncol. 1999 Nov;8(3):155-65 [11113666.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):485-93 [11157996.001]
  • [Cites] Oncol Rep. 2001 Jul-Aug;8(4):931-4 [11410812.001]
  • [Cites] Endocr J. 2001 Apr;48(2):213-7 [11456270.001]
  • [Cites] J Paediatr Child Health. 2002 Jun;38(3):314-7 [12047705.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):676-80 [12434154.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Aug;59(2):180-9 [12864795.001]
  • [Cites] Endocr Pract. 2003 Mar-Apr;9(2):152-6 [12917079.001]
  • [Cites] J Med Genet. 2003 Sep;40(9):657-63 [12960210.001]
  • [Cites] N Engl J Med. 2003 Oct 30;349(18):1722-9 [14585940.001]
  • [Cites] Endocr J. 2003 Aug;50(4):477-9 [14599124.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):900-5 [14983483.001]
  • [Cites] Head Neck. 2004 Aug;26(8):716-26 [15287039.001]
  • [Cites] Ear Nose Throat J. 2004 Jul;83(7):491-4 [15372923.001]
  • [Cites] Clin Nucl Med. 2004 Nov;29(11):681-4 [15483477.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7405-11 [15492263.001]
  • [Cites] Ann Surg. 1969 Apr;169(4):631-40 [4886854.001]
  • [Cites] Cancer. 1973 Mar;31(3):600-5 [4693587.001]
  • [Cites] Cancer. 1982 Jan 15;49(2):388-97 [7053835.001]
  • [Cites] Endocr Rev. 1982 Spring;3(2):218-26 [7044770.001]
  • [Cites] Clin Nephrol. 1982 Sep;18(3):154-8 [7140028.001]
  • [Cites] Surgery. 1983 Dec;94(6):906-15 [6648803.001]
  • [Cites] World J Surg. 1984 Jun;8(3):392-400 [6464494.001]
  • [Cites] Surgery. 1984 Dec;96(6):1132-7 [6505966.001]
  • [Cites] Ann Clin Lab Sci. 1984 Nov-Dec;14(6):458-63 [6239588.001]
  • [Cites] Am J Surg. 1985 Apr;149(4):522-7 [3985291.001]
  • [Cites] Am J Surg. 1985 Jun;149(6):745-8 [4014550.001]
  • [Cites] J Clin Pathol. 1985 Oct;38(10):1114-8 [4056066.001]
  • [Cites] Surgery. 1985 Dec;98(6):1095-100 [4071385.001]
  • [Cites] Laryngoscope. 1987 Feb;97(2):215-8 [3807625.001]
  • [Cites] Surg Clin North Am. 1987 Apr;67(2):343-57 [3551149.001]
  • [Cites] Surgery. 1987 Jun;101(6):649-60 [3589961.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1789-93 [1969327.001]
  • [Cites] Am J Med. 1990 Sep;89(3):327-34 [2393037.001]
  • [Cites] Cancer. 1990 Oct 1;66(7):1555-62 [2208008.001]
  • [Cites] Am Surg. 1991 Jul;57(7):463-7 [1647716.001]
  • [Cites] Surgery. 1991 Oct;110(4):704-8 [1925959.001]
  • [Cites] Surgery. 1991 Dec;110(6):978-86; discussion 986-8 [1745986.001]
  • [Cites] World J Surg. 1991 Nov-Dec;15(6):738-44 [1767540.001]
  • [Cites] Medicine (Baltimore). 1992 Jul;71(4):197-205 [1518393.001]
  • [Cites] World J Surg. 1992 Jul-Aug;16(4):724-31 [1413841.001]
  • [Cites] Am J Surg Pathol. 1993 Aug;17(8):820-9 [8338192.001]
  • [Cites] Surgery. 1993 Nov;114(5):882-92 [8236009.001]
  • [Cites] Surgery. 1993 Dec;114(6):1040-8; discussion 1048-9 [8256207.001]
  • [Cites] N Engl J Med. 1994 Mar 17;330(11):757-61 [7906387.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jun;78(6):1320-4 [8200932.001]
  • [Cites] Aust N Z J Surg. 1994 Jun;64(6):446-9 [8010911.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):594-8; discussion 599 [7725750.001]
  • [Cites] Aust N Z J Surg. 1995 Oct;65(10):714-6 [7487709.001]
  • [Cites] Surg Today. 1995;25(11):984-6 [8640028.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Sep;81(9):3194-6 [8784068.001]
  • [Cites] Curr Opin Nephrol Hypertens. 1996 Jul;5(4):336-41 [8823531.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Aug;45(2):195-200 [8881452.001]
  • [Cites] Surgery. 1996 Nov;120(5):897-901 [8909528.001]
  • [Cites] Nuklearmedizin. 1997 Oct;36(7):256-8 [9394362.001]
  • [Cites] Surgery. 1997 Dec;122(6):1034-8; discussion 1038-9 [9426417.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1083-8 [9543122.001]
  • [Cites] World J Surg. 1999 Jan;23(1):68-74 [9841766.001]
  • [Cites] World J Surg. 1998 Dec;22(12):1225-30 [9841748.001]
  • [Cites] Clin Nucl Med. 1999 Jan;24(1):21-3 [9890488.001]
  • [Cites] Eur J Surg Oncol. 1999 Feb;25(1):100-3 [10188867.001]
  • [Cites] Mod Pathol. 1999 Apr;12(4):412-6 [10229506.001]
  • [Cites] Cancer. 1999 Aug 1;86(3):538-44 [10430265.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1287-92 [15517474.001]
  • [Cites] Oncogene. 2005 Feb 10;24(7):1272-6 [15580289.001]
  • [Cites] Eur J Endocrinol. 2005 Mar;152(3):459-70 [15757864.001]
  • [Cites] Ann Surg Oncol. 2005 Mar;12(3):260-6 [15827819.001]
  • [Cites] Endocr Pathol. 2005 Spring;16(1):49-52 [16000846.001]
  • [Cites] World J Surg. 2006 May;30(5):705-13 [16680586.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1140-9 [16931959.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Sep;67(3):370-6 [17555500.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Oct;92(10):3803-8 [17666472.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3216-22 [17805932.001]
  • [Cites] Surgery. 2007 Dec;142(6):1022-6 [18063090.001]
  • [Cites] Clin Nucl Med. 2008 Mar;33(3):196-7 [18287845.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2008 Aug;116(8):487-90 [18095236.001]
  • [Cites] Eur J Endocrinol. 2008 Oct;159(4):469-74 [18625691.001]
  • [Cites] Int J Surg Pathol. 2008 Oct;16(4):458-60 [18701514.001]
  • (PMID = 20051478.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK088188
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDC73 protein, human; 0 / Naphthalenes; 0 / Parathyroid Hormone; 0 / Tumor Suppressor Proteins; 1K860WSG25 / Cinacalcet Hydrochloride
  • [Number-of-references] 86
  • [Other-IDs] NLM/ PMC3227890
  •  go-up   go-down


23. Navarro-González JF, Mora-Fernández C, García-Pérez J: Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Semin Dial; 2009 Jan-Feb;22(1):37-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Potential harmful effects of elevated Mg include altered nerve conduction velocity, increased pruritus, and alterations to osseous metabolism and parathyroid gland function (mineralization defects, contribution to osteomalacic renal osteodystrophy, and adynamic bone disease).


24. Kawata T, Imanishi Y, Kobayashi K, Onoda N, Takemoto Y, Tahara H, Okuno S, Ishimura E, Miki T, Ishikawa T, Inaba M, Nishizawa Y: Direct in vitro evidence of extracellular Ca2+-induced amino-terminal truncation of human parathyroid hormone (1-84) by human parathyroid cells. J Clin Endocrinol Metab; 2005 Oct;90(10):5774-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct in vitro evidence of extracellular Ca2+-induced amino-terminal truncation of human parathyroid hormone (1-84) by human parathyroid cells.
  • CONTEXT: Although serum calcium (Ca2+) concentration regulates the generation of amino-terminally (N-terminally) truncated forms of human PTH (hPTH) degraded from (1-84)hPTH, no studies have yet reported whether the parathyroid gland itself is responsible for this process.
  • OBJECTIVE: Our objective was to determine the site of N-terminal truncation and its roles in PTH metabolism in parathyroid cells in vitro.
  • METHODS: The effect of extracellular Ca2+ concentration was examined on N-terminal truncation in primary cultured parathyroid cells.
  • The parathyroid glands were obtained from the patients with primary and uremia-associated secondary hyperparathyroidisms who underwent therapeutic parathyroidectomies.
  • Suppression of PTH secretion by increasing the extracellular Ca2+ concentration was more evident with the Bio-PTH assay than with the I-PTH assay for both cultured parathyroid cells prepared from parathyroid adenomas and uremia-associated secondary hyperparathyroidism.
  • CONCLUSIONS: These findings suggest that the N-terminal truncation is regulated by extracellular Ca2+ concentration and works to suppress the generation of (1-84)hPTH in parathyroid cells.
  • [MeSH-major] Calcium / pharmacology. Parathyroid Glands / drug effects. Parathyroid Glands / metabolism. Parathyroid Hormone / metabolism

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16046589.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 0 / Peptide Fragments; SY7Q814VUP / Calcium
  •  go-up   go-down


25. Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM: Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant; 2005 Oct;20(10):2186-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients with secondary hyperparathyroidism often require therapy that provides long-term control of parathyroid hormone concentrations without increasing calcium and phosphorus concentrations.
  • Cinacalcet modulates the calcium-sensing receptor on the parathyroid gland to reduce secretion of parathyroid hormone and lower serum calcium, phosphorus and calcium-phosphorus product in haemodialysis patients.
  • METHODS: Dialysis patients with secondary hyperparathyroidism [parathyroid hormone (PTH) level > or =300 pg/ml] who were enrolled in one of four phase 2 placebo-controlled studies were eligible to enroll in an open-label extension study in which all patients received cinacalcet.
  • [MeSH-minor] Adult. Aged. Calcium / blood. Cinacalcet Hydrochloride. Female. Humans. Kidney Failure, Chronic / complications. Male. Middle Aged. Parathyroid Hormone / blood. Phosphorus / blood. Receptors, Calcium-Sensing / drug effects. Receptors, Calcium-Sensing / metabolism. Time Factors

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030053.001).
  • [ISSN] 0931-0509
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Naphthalenes; 0 / Parathyroid Hormone; 0 / Receptors, Calcium-Sensing; 1K860WSG25 / Cinacalcet Hydrochloride; 27YLU75U4W / Phosphorus; SY7Q814VUP / Calcium
  •  go-up   go-down


26. Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S, Sasano H: Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J; 2005 Oct;52(5):605-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among human tissues in which the presence of sstr has not been previously reported, the parotid gland demonstrated immunoreactivity for sstr2B and sstr5, bronchial gland for sstr1, 2B, 3, 4, 5, parathyroid gland for sstr1, 3, 4, and duodenum for all subtypes immunoreactivity.
  • In stomach, all subtypes of receptor were detected in various cell types of the mucosa, but none in ECL cells of fundic gland.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284440.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 3; 0 / somatostatin receptor 5; 0 / somatostatin receptor subtype-4; 0 / somatostatin receptor type 1
  •  go-up   go-down


27. Ivins S, Lammerts van Beuren K, Roberts C, James C, Lindsay E, Baldini A, Ataliotis P, Scambler PJ: Microarray analysis detects differentially expressed genes in the pharyngeal region of mice lacking Tbx1. Dev Biol; 2005 Sep 15;285(2):554-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Real-time quantitative PCR and in situ hybridization validated diminished expression of Pax9 and Gcm2, genes known to be required for normal thymus and parathyroid gland morphogenesis, whereas Pax1, Hoxa3, Eya1, and Foxn1, which are similarly required, were not down-regulated.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109395.001).
  • [ISSN] 0012-1606
  • [Journal-full-title] Developmental biology
  • [ISO-abbreviation] Dev. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Paired Box Transcription Factors; 0 / Pax9 protein, mouse; 0 / T-Box Domain Proteins; 0 / Tbx1 protein, mouse
  •  go-up   go-down


28. Arey BJ, Seethala R, Ma Z, Fura A, Morin J, Swartz J, Vyas V, Yang W, Dickson JK Jr, Feyen JH: A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo. Endocrinology; 2005 Apr;146(4):2015-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo.
  • The expression of the CaR suggests a critical role in cellular regulation by calcium in various organs, including parathyroid gland, bone, and kidney.
  • [MeSH-major] Naphthalenes / pharmacology. Parathyroid Hormone / secretion. Receptors, Calcium-Sensing / antagonists & inhibitors

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15637285.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / N-(2-hydroxy-3-(2-cyano-3-chlorophenoxy)propyl)-1,1-dimethyl-2-(2-nephthyl)ethylamine; 0 / Naphthalenes; 0 / Parathyroid Hormone; 0 / Receptors, Calcium-Sensing; SY7Q814VUP / Calcium
  •  go-up   go-down


29. Guillem P, Vlaeminck-Guillem V, Dracon M, Noel C, Cussac JF, Huglo D, Proye C: [Are preoperative examinations useful in the management of patients with renal hyperparathyroidism?]. Ann Chir; 2006 Jan;131(1):27-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM OF THE STUDY: To evaluate the efficiency of preoperative parathyroid ultrasonography and scintigraphy in the management of renal hyperparathyroidism.
  • PATIENTS AND METHODS: The charts of the last consecutive 200 patients who underwent surgery for renal hyperparathyroidism from 1998 to 2003 were retrospectively reviewed to collect data concerning parathyroid gland function, results of preoperative ultrasonography and scintigraphy, as well as modalities and results of surgical exploration.
  • CONCLUSION: Parathyroid ultrasonography and scintigraphy are of poor interest in the management of renal hyperparathyroidism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16375845.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


30. Huh SH, Ornitz DM: Beta-catenin deficiency causes DiGeorge syndrome-like phenotypes through regulation of Tbx1. Development; 2010 Apr;137(7):1137-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we show that canonical Wnt-beta-catenin signaling negatively regulates Tbx1 expression and that mesenchymal inactivation of beta-catenin (Ctnnb1) in mice caused abnormalities within the DGS phenotypic spectrum, including great vessel malformations, hypoplastic pulmonary and aortic arch arteries, cardiac malformations, micrognathia, thymus hypoplasia and mislocalization of the parathyroid gland.

  • Genetic Alliance. consumer health - 22q11.2 Deletion Syndrome.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2002 Apr 15;11(8):915-22 [11971873.001]
  • [Cites] Nat Rev Genet. 2001 Nov;2(11):858-68 [11715041.001]
  • [Cites] Hum Mol Genet. 2002 Oct 1;11(20):2363-9 [12351571.001]
  • [Cites] Cell. 2002 Nov 27;111(5):673-85 [12464179.001]
  • [Cites] Genes Dev. 2003 Jan 15;17(2):269-81 [12533514.001]
  • [Cites] Cell. 2003 Jan 24;112(2):169-80 [12553906.001]
  • [Cites] Am J Med Genet A. 2003 Jun 15;119A(3):251-6 [12784288.001]
  • [Cites] Lancet. 2003 Oct 25;362(9393):1342-3 [14585631.001]
  • [Cites] Hum Mol Genet. 2004 Aug 1;13(15):1577-85 [15190012.001]
  • [Cites] Development. 2004 Nov;131(21):5491-502 [15469978.001]
  • [Cites] Genes Dev. 1991 Jan;5(1):105-19 [1989904.001]
  • [Cites] Dev Dyn. 1996 Aug;206(4):379-90 [8853987.001]
  • [Cites] Curr Biol. 1998 Dec 3;8(24):1323-6 [9843687.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Development. 1999 Oct;126(20):4557-68 [10498690.001]
  • [Cites] Development. 2005 Jan;132(1):49-60 [15576404.001]
  • [Cites] Genes Dev. 2005 Mar 1;19(5):530-5 [15741317.001]
  • [Cites] Dev Cell. 2005 May;8(5):739-50 [15866164.001]
  • [Cites] Development. 2005 Sep;132(17):3847-57 [16049112.001]
  • [Cites] Dev Cell. 2006 Jan;10(1):81-92 [16399080.001]
  • [Cites] Development. 2006 Jun;133(12):2419-33 [16720879.001]
  • [Cites] Development. 2006 Jun;133(12):2435-45 [16720880.001]
  • [Cites] Development. 2006 Sep;133(18):3587-95 [16914493.001]
  • [Cites] Bioessays. 2006 Nov;28(11):1078-86 [17041894.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Am J Hum Genet. 2007 Mar;80(3):510-7 [17273972.001]
  • [Cites] Development. 2007 Apr;134(8):1593-604 [17344228.001]
  • [Cites] Eur J Hum Genet. 2007 Jun;15(6):658-63 [17377518.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 29;104(22):9319-24 [17519332.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 29;104(22):9313-8 [17519333.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10894-9 [17576928.001]
  • [Cites] J Clin Invest. 2007 Jul;117(7):1794-804 [17607356.001]
  • [Cites] Dev Cell. 2007 Jul;13(1):10-3 [17609106.001]
  • [Cites] Nature. 2007 Nov 8;450(7167):285-8 [17994097.001]
  • [Cites] Development. 2008 Jan;135(2):193-205 [18156162.001]
  • [Cites] PLoS One. 2008;3(1):e1516 [18231602.001]
  • [Cites] Cell Stem Cell. 2007 Aug 16;1(2):165-79 [18371348.001]
  • [Cites] Dev Biol. 2008 Jul 15;319(2):426-36 [18533146.001]
  • [Cites] Dev Dyn. 2008 Oct;237(10):3059-70 [18816858.001]
  • [Cites] Dev Growth Differ. 2008 Dec;50(9):717-29 [19046160.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):5931-42 [10545105.001]
  • [Cites] Development. 2000 Apr;127(8):1607-16 [10725237.001]
  • [Cites] Hum Mol Genet. 2000 Oct;9(16):2421-6 [11005797.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):97-101 [11242049.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):286-91 [11242110.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):293-8 [11242111.001]
  • [Cites] Cell. 2001 Feb 23;104(4):619-29 [11239417.001]
  • [Cites] Development. 2001 Apr;128(8):1253-64 [11262227.001]
  • [Cites] Dev Biol. 2001 Jul 1;235(1):62-73 [11412027.001]
  • [Cites] Development. 2002 Oct;129(19):4605-11 [12223416.001]
  • (PMID = 20215350.001).
  • [ISSN] 1477-9129
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD049808; United States / NICHD NIH HHS / HD / HD049808
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fgf8 protein, mouse; 0 / Repressor Proteins; 0 / T-Box Domain Proteins; 0 / TBX1 protein, human; 0 / Tbx1 protein, mouse; 0 / Twist Transcription Factor; 0 / Twist2 protein, mouse; 0 / Wnt Proteins; 0 / beta Catenin; 148997-75-5 / Fibroblast Growth Factor 8
  • [Other-IDs] NLM/ PMC2835329
  •  go-up   go-down


31. Gold JS, Donovan PI, Udelsman R: Partial median sternotomy: an attractive approach to mediastinal parathyroid disease. World J Surg; 2006 Jul;30(7):1234-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial median sternotomy: an attractive approach to mediastinal parathyroid disease.
  • BACKGROUND: Parathyroid exploration through a standard cervical approach is adequate for the resection of most mediastinal parathyroid glands.
  • A subset of mediastinal parathyroid glands causing hyperparathyroidism, however, cannot be removed in this manner.
  • Six of these seven patients had failed a previous parathyroid exploration (86%), including one patient who had a previous complete sternotomy.
  • In five patients a mediastinal parathyroid gland was removed (71%), and in one patient a parathyroid adenoma in the carotid sheath was eventually found, and the location of the hyperfunctioning parathyroid gland in one patient was never determined although the patient was cured.
  • CONCLUSIONS: Rarely, mediastinal parathyroid glands cannot be resected through a cervical approach.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):204-8 [12118759.001]
  • [Cites] J Heart Valve Dis. 1996 Nov;5(6):638-40 [8953441.001]
  • [Cites] Ann Thorac Surg. 1982 Oct;34(4):473-4 [7138118.001]
  • [Cites] Am J Surg. 1969 May;117(5):705 [5791042.001]
  • [Cites] Ann Thorac Surg. 1966 Jul;2(4):532-9 [5934068.001]
  • [Cites] Langenbecks Arch Surg. 2002 Jan;386(7):488-93 [11819104.001]
  • [Cites] Ann Thorac Surg. 1999 Jan;67(1):263-5 [10086573.001]
  • [Cites] Br J Surg. 1978 May;65(5):297-300 [647190.001]
  • [Cites] Int Surg. 1982 Jan-Mar;67(1):13-6 [7095997.001]
  • [Cites] Am Surg. 1983 Oct;49(10):523-7 [6678542.001]
  • [Cites] Am Surg. 1991 Jan;57(1):62-6 [1796800.001]
  • [Cites] Surgery. 1978 Sep;84(3):384-93 [98860.001]
  • [Cites] World J Surg. 1985 Oct;9(5):807-13 [4060751.001]
  • [Cites] Ann Thorac Surg. 2000 Oct;70(4):1423-4; discussion 1425 [11081921.001]
  • [Cites] Chest Surg Clin N Am. 1996 Feb;6(1):85-93 [8646506.001]
  • [Cites] J Thorac Cardiovasc Surg. 1984 Jan;87(1):124-9 [6690849.001]
  • [Cites] Am J Surg. 1982 Mar;143(3):296-300 [7065348.001]
  • [Cites] Ann Surg. 1976 Feb;183(2):139-145 [1247311.001]
  • [Cites] Curr Probl Surg. 1980 Aug;17(8):398-463 [6998661.001]
  • [Cites] Ann Surg. 1991 Nov;214(5):555-61 [1953107.001]
  • [Cites] Ann Surg. 1977 Aug;186(2):140-5 [889360.001]
  • [Cites] J Heart Valve Dis. 2003 Jan;12(1):76-80 [12578340.001]
  • [Cites] Ann Surg. 1981 Jun;193(6):805-9 [7247524.001]
  • [Cites] Ann Surg. 1992 Feb;215(2):101-6 [1546895.001]
  • [Cites] Ann Thorac Surg. 2000 Jan;69(1):221-3 [10654517.001]
  • [Cites] Surgery. 1987 Dec;102(6):949-57 [3686358.001]
  • [Cites] Metabolism. 1962 Jan;11:21-9 [13865885.001]
  • [Cites] Mayo Clin Proc. 1991 Nov;66(11):1110-3 [1943241.001]
  • [Cites] World J Surg. 1986 Aug;10(4):687-95 [3751094.001]
  • [Cites] Int Surg. 1987 Apr-Jun;72(2):104-8 [3610535.001]
  • [Cites] Ann Thorac Surg. 1999 Dec;68(6):2209-13; discussion 2213-4 [10617004.001]
  • [Cites] Ann Surg. 1976 Mar;183(3):271-5 [1259483.001]
  • [Cites] Cardiovasc Surg. 2002 Aug;10(4):333-8 [12359403.001]
  • [Cites] Arch Surg. 1988 Sep;123(9):1096-100 [3415460.001]
  • (PMID = 16794907.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Vulpio C, Bossola M, De Gaetano A, Maresca G, Panocchia N, Spada P, Tazza L, Luciani G, Castagneto M: [Ultrasound parameter-based response to treatment with new drugs for secondary hyperparathyroidism: a retrospective analysis in a single dialysis center]. G Ital Nefrol; 2010 Sep-Oct;27(5):527-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In hemodialysis patients with secondary hyperparathyroidism (SHPT) ultrasonography of the parathyroid glands allows to assess the glandular growth and to define the limits of medical treatment.
  • The present retrospective study evaluated the relationship between parathyroid gland hyperplasia and the effectiveness of new drugs.
  • These patients underwent parathyroid ultrasonography and sequential therapy with intravenous calcitriol (first step), paracalcitol (second step), and paracalcitol + cinacalcet (third step).
  • The therapeutic response was correlated with ultrasound parameters (number of parathyroid glands, maximum longitudinal diameter, structural score, and vascular score).
  • ROC curve analysis showed that maximum longitudinal diameter (< 9 mm), number of parathyroid glands (< -1), structural score (< 2), and vascular score (< 2) predicted response to any treatment.
  • Thus parathyroid gland ultrasonography predicts the therapeutic response also to the new drugs.

  • Hazardous Substances Data Bank. PARICALCITOL .
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20922685.001).
  • [ISSN] 0393-5590
  • [Journal-full-title] Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
  • [ISO-abbreviation] G Ital Nefrol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Ergocalciferols; 0 / Naphthalenes; 1K860WSG25 / Cinacalcet Hydrochloride; 6702D36OG5 / paricalcitol; FXC9231JVH / Calcitriol
  •  go-up   go-down


33. Temmim L, Sinowatz F, Hussein WI, Al-Sanea O, El-Khodary H: Intrathyroidal parathyroid carcinoma: a case report with clinical and histological findings. Diagn Pathol; 2008;3:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathyroidal parathyroid carcinoma: a case report with clinical and histological findings.
  • The chance of an intrathyroidal occurrence of a parathyroid gland is about 1-3%.
  • Among the causes of hyperparathyroidism, parathyroid cases occur in less than 1% of patients.
  • Here we present the case of a 63 year old Saudi female suffering from an intrathyroidal parathyroid carcinoma.
  • The suspicion coming from the clinical investigations that the removed tumor tissue may be a parathyroid carcinoma could be confirmed by histology.
  • Although parathyroid adenoma and carcinoma have disparate natural history, it can be difficult to differentiate between the two entities.
  • Clinical presentation, operative findings may raise suspicion, but may not be conclusive especially if there is no evidence of invasion or metastasis, especially if the gland was intrathyroidal.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Pathol. 2008;3:2 [18190715.001]
  • [Cites] Surg Oncol. 1999 Nov;8(3):155-65 [11113666.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4803-7 [17214344.001]
  • [Cites] Sao Paulo Med J. 2006 Jan 5;124(1):42-4 [16612462.001]
  • [Cites] Bull Cancer. 2006 Mar 1;93(3):283-7 [16567315.001]
  • [Cites] Anat Histol Embryol. 2006 Apr;35(2):125-9 [16542178.001]
  • [Cites] World J Surg Oncol. 2006;4:1 [16393338.001]
  • [Cites] World J Surg Oncol. 2005 Jun 23;3:39 [15975144.001]
  • [Cites] Mod Pathol. 1999 Apr;12(4):412-6 [10229506.001]
  • [Cites] Thyroid. 1998 Jul;8(7):597-9 [9709913.001]
  • [Cites] J Clin Endocrinol Metab. 1996 May;81(5):1736-9 [8626826.001]
  • [Cites] Am J Pathol. 1984 Apr;115(1):70-83 [6711681.001]
  • [Cites] Otolaryngol Head Neck Surg. 2002 Oct;127(4):352-3 [12402018.001]
  • [Cites] J Surg Oncol. 2001 Jun;77(2):136-8 [11398168.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):485-93 [11157996.001]
  • [Cites] Diagn Pathol. 2007;2:39 [17939859.001]
  • (PMID = 19032735.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2627811
  •  go-up   go-down


34. Dusková J: Known pitfalls of the thyroid neoplasm diagnostics in the view of the new (2004) WHO Classification. Cesk Patol; 2006 Jan;42(1):24-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Known pitfalls of the thyroid neoplasm diagnostics in the view of the new (2004) WHO Classification.
  • The new (2004) WHO Classification of Tumours of the Thyroid and Parathyroid Gland exhibits both formal and contentual changes compared to the previous one from the year 1988.
  • This is true especially for the borderline neoplasm in the FVPTC category and even more for its oncocytic variant.
  • There appeared shift in the criteria for the diagnosis of oncocytic variant of papillary carcinoma.
  • The post aspiration capsular damage consideration in relation to the diagnosis of the minimally invasive follicular carcinoma is one practical profit thereof.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16506598.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


35. Babademez MA, Tuncay KS, Zaim M, Acar B, Karaşen RM: Hashimoto thyroiditis and thyroid gland anomalies. J Craniofac Surg; 2010 Nov;21(6):1807-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hashimoto thyroiditis and thyroid gland anomalies.
  • There are several thyroid gland developmental anomalies such as presence of a pyramidal lobe, absence of the lateral lobes, absence of the isthmus or incomplete isthmus, and significantly asymmetric lateral lobes.
  • In this report, we present a case with Hashimoto thyroiditis and thyroid gland anomalies that consist of thyroglossal duct remnant and absence of the isthmus.
  • Furthermore, an anomaly in the parathyroid gland location and morphologic anomaly as a cystic parathyroid gland were seen in our case.
  • [MeSH-major] Hashimoto Disease / pathology. Parathyroid Glands / abnormalities. Thyroglossal Cyst / pathology. Thyroid Gland / abnormalities

  • Genetic Alliance. consumer health - Hashimoto's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119426.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Shimane T, Mori T, Ono T, Egawa S, Furuta A, Ikeda K, Kamakazu K, Kobayashi S, Sanbe T, Suzaki H: [Three cases of adenocarcinoma of the head and neck maintaining QOL by administration of docetaxel]. Gan To Kagaku Ryoho; 2010 Dec;37(13):2897-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each case had submandibular gland carcinoma, parotid gland carcinoma, or parathyroid gland carcinoma.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160265.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


37. Priya G, Jyotsna VP, Gupta N, Chumber S, Bal CS, Karak AK, Seth A, Ammini AC: Clinical and laboratory profile of primary hyperparathyroidism in India. Postgrad Med J; 2008 Jan;84(987):34-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical and biochemical details, including serum calcium, phosphate, alkaline phosphatase, parathyroid hormone (PTH) and 25OHD levels, were recorded.
  • An abbreviated skeletal survey and preoperative localisation with ultrasound/CT scan of the neck and tetrofosmin/technetium-99m hexakis(2-methoxyisobutylisonitrile) parathyroid scan was performed.
  • Serum alkaline phosphatase, PTH and gland weight were higher, whereas serum 25OHD was lower, in patients with skeletal disease.
  • Parathyroid gland weight was found to correlate with serum calcium and PTH.
  • [MeSH-minor] Adolescent. Adult. Aged. Alkaline Phosphatase / blood. Child. Female. Humans. India. Male. Middle Aged. Organ Size. Parathyroid Glands / anatomy & histology


38. Rubello D, Nanni C, Merante Boschin I, Toniato A, Piotto A, Rampin L, Mariani G, Al-Nahhas A, Pelizzo MR: Sentinel lymph node (SLN) procedure with patent V blue dye in 153 patients with papillary thyroid carcinoma (PTC): is it an accurate staging method? J Exp Clin Cancer Res; 2006 Dec;25(4):483-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients had a preoperative cytological diagnosis of PTC, and none had clinical or ultrasonographic (US) evidence of nodal involvement.
  • Subsequently, total thyroidectomy, central compartment (CC) node dissection, and median inferior jugulocarotid node dissection of laterocervical compartment, ipsilateral to the primary tumour, were performed.
  • In 4 cases, a normal parathyroid gland and in 3 cases fibro-adipous tissue were blue-stained and mistakenly removed as SLN (7 false positive results).
  • [MeSH-minor] Biopsy / methods. Coloring Agents. Humans. Neoplasm Staging. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17310837.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Coloring Agents
  •  go-up   go-down


39. Agarwal G, Prasad KK, Kar DK, Krishnani N, Pandey R, Mishra SK: Indian primary hyperparathyroidism patients with parathyroid carcinoma do not differ in clinicoinvestigative characteristics from those with benign parathyroid pathology. World J Surg; 2006 May;30(5):732-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indian primary hyperparathyroidism patients with parathyroid carcinoma do not differ in clinicoinvestigative characteristics from those with benign parathyroid pathology.
  • INTRODUCTION: No foolproof preoperative diagnostic indicators of parathyroid carcinoma (PC) exist in absence of nonskeletal metastases.
  • Palpable parathyroid tumor, advanced skeletal and renal manifestations, and very high serum calcium and parathyroid hormone levels are considered strong predictors.
  • Various parameters of patient groups with parathyroid adenoma (n = 84), primary hyperplasia (n = 12), and carcinoma (n = 4) were compared using ANOVA, with P value < 0.05 considered significant.
  • Two patients with PC and 27 (32%) with adenoma had palpable parathyroid tumor.
  • Mean tumor weight (milligram) in carcinoma patients (15,080 +/- 5,638.02) was significantly higher than those with adenoma (5,724 +/- 1,257.9) (P = 0.002).
  • CONCLUSION: Indian patients with parathyroid adenoma, hyperplasia, and carcinoma were not found to differ in their clinical, biochemical, and pathological characteristics except for significantly higher tumor weight in the carcinoma group.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma / diagnosis. Hyperparathyroidism, Primary / etiology. Parathyroid Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Hyperplasia / diagnosis. India. Male. Middle Aged. Parathyroid Diseases / diagnosis. Predictive Value of Tests

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):344-9 [11859206.001]
  • [Cites] World J Surg. 1992 Jul-Aug;16(4):724-31 [1413841.001]
  • [Cites] World J Surg. 1991 Nov-Dec;15(6):738-44 [1767540.001]
  • [Cites] J Surg Oncol. 2004 Dec 15;88(4):223-8 [15565599.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Sep;89(5):367-75 [7315334.001]
  • [Cites] Surg Clin North Am. 1987 Apr;67(2):343-57 [3551149.001]
  • [Cites] Surgery. 1983 Dec;94(6):906-15 [6648803.001]
  • [Cites] Semin Surg Oncol. 1997 Mar-Apr;13(2):104-13 [9088066.001]
  • [Cites] Ann Surg Oncol. 2005 Jul;12(7):526-32 [15889214.001]
  • [Cites] Arch Surg. 1979 Apr;114(4):468-74 [435060.001]
  • [Cites] Miner Electrolyte Metab. 1987;13(5):305-10 [3312988.001]
  • [Cites] J R Coll Surg Edinb. 1998 Dec;43(6):424-7 [9990797.001]
  • [Cites] World J Surg. 1984 Jun;8(3):392-400 [6464494.001]
  • [Cites] Curr Treat Options Oncol. 2001 Aug;2(4):347-54 [12057115.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Sep;43(3):351-8 [7586606.001]
  • [Cites] Am J Surg. 1985 Apr;149(4):522-7 [3985291.001]
  • [Cites] Rev Invest Clin. 2000 Nov-Dec;52(6):618-24 [11256104.001]
  • [Cites] Eur J Surg. 1996 Oct;162(10):777-81 [8934106.001]
  • [Cites] Endocr Rev. 1982 Spring;3(2):218-26 [7044770.001]
  • [Cites] Surgery. 1990 Jan;107(1):13-9 [2296753.001]
  • [Cites] Endocr Pathol. 2005 Spring;16(1):49-52 [16000846.001]
  • [Cites] J Pak Med Assoc. 1999 Aug;49(8):194-8 [10641503.001]
  • [Cites] Cancer. 1973 Mar;31(3):600-5 [4693587.001]
  • [Cites] Br J Surg. 2001 May;88(5):708-14 [11350446.001]
  • [Cites] Surgery. 1991 Oct;110(4):704-8 [1925959.001]
  • [Cites] Indian J Pathol Microbiol. 2006 Jul;49(3):448-50 [17001919.001]
  • [Cites] Hum Pathol. 1986 May;17(5):520-7 [3699813.001]
  • [Cites] Pathol Annu. 1981;16(Pt 2):1-24 [7036057.001]
  • [Cites] Indian J Med Res. 1985 Jun;81:607-12 [4054967.001]
  • [Cites] Endocr Pract. 2002 Jul-Aug;8(4):266-70 [12173912.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jan;83(1):169-73 [9435436.001]
  • [Cites] Ann Acad Med Singapore. 2001 Jan;30(1):66-70 [11242630.001]
  • [Cites] Ann Saudi Med. 2005 Jan-Feb;25(1):29-35 [15822491.001]
  • [Cites] Arch Surg. 1979 Apr;114(4):475-80 [435061.001]
  • [Cites] Surgery. 2002 Dec;132(6):1075-83; discussion 1083-5 [12490858.001]
  • [Cites] Adv Anat Pathol. 2005 Mar;12(2):53-61 [15731573.001]
  • [Cites] World J Surg. 1988 Aug;12 (4):517-21 [3420934.001]
  • [Cites] Indian J Pathol Microbiol. 2004 Jan;47(1):39-40 [15471124.001]
  • [Cites] Rev Med Chil. 1993 Mar;121(3):265-72 [8248638.001]
  • (PMID = 16680588.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Cannata-Andía JB, Rodriguez-García M, Román-García P, Tuñón-le Poultel D, López-Hernández F, Rodríguez-Puyol D: New therapies: calcimimetics, phosphate binders and vitamin D receptor activators. Pediatr Nephrol; 2010 Apr;25(4):609-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Calcimimetics increase the sensitivity of the parathyroid gland to calcium through spatial configurational changes of the calcium-sensing receptor.
  • New vitamin D receptor activators, such as paricalcitol, are as effective at suppressing parathyroid hormone (PTH) as the traditional vitamin D receptor activators used for the past two decades, but they have a better and safer profile, showing fewer calcaemic and phosphoraemic effects while preserving the desirable effects of the vitamin D receptor activators on the cardiovascular system, hypertension, inflammation and fibrosis.
  • [MeSH-minor] Bone Density Conservation Agents / therapeutic use. Chelating Agents / therapeutic use. Child. Cinacalcet Hydrochloride. Ergocalciferols / therapeutic use. Humans. Kidney Failure, Chronic / drug therapy. Kidney Failure, Chronic / metabolism. Naphthalenes / therapeutic use. Parathyroid Glands. Polyamines / therapeutic use. Protein Binding. Sevelamer

  • Hazardous Substances Data Bank. PARICALCITOL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kidney Int. 2008 Oct;74(8):1070-8 [18633342.001]
  • [Cites] Nephron Physiol. 2007;106(4):p76-81 [17622742.001]
  • [Cites] J Am Soc Nephrol. 2009 Feb;20(2):388-96 [19092121.001]
  • [Cites] Nephrol Dial Transplant. 2008 Jul;23(7):2311-8 [18310602.001]
  • [Cites] Pediatr Nephrol. 2008 Oct;23(10):1831-6 [18575896.001]
  • [Cites] Endocrinology. 2008 Feb;149(2):558-64 [17974622.001]
  • [Cites] Am J Kidney Dis. 2009 Feb;53(2):197-207 [19110359.001]
  • [Cites] Circulation. 2001 Feb 20;103(7):987-92 [11181474.001]
  • [Cites] Nephrol Ther. 2007 Oct;3 Suppl 3:S156-61 [18340681.001]
  • [Cites] J Clin Invest. 1990 Dec;86(6):1968-75 [2174913.001]
  • [Cites] Hypertension. 2008 Aug;52(2):249-55 [18606901.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):16810-5 [17942703.001]
  • [Cites] Pediatr Nephrol. 2006 Oct;21(10):1434-9 [16900383.001]
  • [Cites] Am J Physiol. 1997 Apr;272(4 Pt 2):H1751-8 [9139959.001]
  • [Cites] J Am Soc Nephrol. 2005 Aug;16(8):2501-8 [15944337.001]
  • [Cites] QJM. 2002 Dec;95(12):787-96 [12454321.001]
  • [Cites] Am J Physiol Renal Physiol. 2007 May;292(5):F1390-5 [17200160.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jul 26;212(3):861-7 [7626122.001]
  • [Cites] J Am Soc Nephrol. 2004 Oct;15(10 ):2579-87 [15466262.001]
  • [Cites] Arthritis Rheum. 2005 Jan;52(1):290-5 [15641045.001]
  • [Cites] J Am Soc Nephrol. 2006 Dec;17 (12 ):3382-93 [17082242.001]
  • [Cites] Kidney Int. 1987 Sep;32(3):388-94 [3669498.001]
  • [Cites] Kidney Int. 2009 Jan;75(1):88-95 [18843258.001]
  • [Cites] J Pediatr. 2009 Jun;154(6):906-11.e1 [19230902.001]
  • [Cites] Nephrol Dial Transplant. 2009 Mar;24(3):982-9 [19181759.001]
  • [Cites] Nephron Clin Pract. 2005;100(1):c8-19 [15809508.001]
  • [Cites] Kidney Int Suppl. 1999 Dec;73:S14-9 [10633458.001]
  • [Cites] Nat Rev Nephrol. 2009 Jun;5(6):307-8 [19474823.001]
  • [Cites] Am J Nephrol. 2009;29(2):71-8 [18689981.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1516-25 [15071126.001]
  • [Cites] Semin Dial. 2007 Jul-Aug;20(4):329-32 [17635823.001]
  • [Cites] Kidney Int Suppl. 2003 Jun;(85):S44-8 [12753264.001]
  • [Cites] J Clin Invest. 1996 Jun 1;97(11):2534-40 [8647946.001]
  • [Cites] Nephrol Dial Transplant. 2008 Sep;23(9):2761-7 [18408076.001]
  • [Cites] Bone. 2000 Oct;27(4):511-9 [11033446.001]
  • [Cites] J Clin Invest. 1995 Oct;96(4):1786-93 [7560070.001]
  • [Cites] Bone. 2000 Feb;26(2):175-82 [10678413.001]
  • [Cites] Am J Kidney Dis. 2008 Sep;52(3):519-30 [18514987.001]
  • [Cites] Am J Kidney Dis. 2007 Jun;49(6):814-23 [17533024.001]
  • [Cites] Scand J Urol Nephrol. 1997 Jun;31(3):275-80 [9249893.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15896-901 [18838678.001]
  • [Cites] Eur J Clin Nutr. 2008 Sep;62(9):1079-89 [17538533.001]
  • [Cites] Nephrol Dial Transplant. 2008 Nov;23 (11):3677-84 [18577536.001]
  • [Cites] Kidney Int. 2007 Oct;72(8):1004-13 [17687259.001]
  • [Cites] Kidney Int. 2007 Jan;71(1):31-8 [17091124.001]
  • [Cites] Nephrol Dial Transplant. 2002 May;17(5):723-31 [11981055.001]
  • [Cites] Nephrol Dial Transplant. 2002 Nov;17(11):1875-8 [12401838.001]
  • [Cites] Kidney Int. 2009 May;75(9):906-14 [19279554.001]
  • [Cites] Kidney Int. 2008 Oct;74(7):966; author reply 966-7 [18794826.001]
  • [Cites] Nephron Clin Pract. 2008;110(1):c15-23 [18667837.001]
  • [Cites] Nephrol Dial Transplant. 2002;17 Suppl 2:9-12 [11904351.001]
  • [Cites] J Biol Chem. 1987 Feb 25;262(6):2536-41 [3818607.001]
  • [Cites] Nefrologia. 2009;29(2):103-8 [19396314.001]
  • [Cites] J Am Soc Nephrol. 2004 Nov;15(11):2857-67 [15504939.001]
  • [Cites] Nature. 1993 Dec 9;366(6455):575-80 [8255296.001]
  • [Cites] Toxicol Lett. 2007 Jun 15;171(1-2):69-77 [17570622.001]
  • [Cites] Nephrol Dial Transplant. 2004 Jan;19(1):179-84 [14671054.001]
  • [Cites] N Engl J Med. 2000 May 18;342(20):1478-83 [10816185.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Jan;288(1):E125-32 [15367398.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Nov;1(4):307-15 [11706745.001]
  • [Cites] Kidney Int. 2002 Jul;62(1):245-52 [12081584.001]
  • [Cites] Am Heart J. 2005 May;149(5):820-5 [15894962.001]
  • [Cites] Kidney Int. 2005 Dec;68(6):2823-8 [16316359.001]
  • [Cites] Am J Nephrol. 2004 Sep-Oct;24(5):503-10 [15452403.001]
  • [Cites] Am J Physiol Renal Physiol. 2009 Dec;297(6):F1502-9 [19625376.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):446-56 [12890843.001]
  • [Cites] J Am Soc Nephrol. 2009 Feb;20(2):234-6 [19176696.001]
  • [Cites] Clin J Am Soc Nephrol. 2007 Sep;2(5):898-905 [17702710.001]
  • [Cites] Pediatr Nephrol. 2008 Oct;23(10):1817-22 [18288502.001]
  • [Cites] Kidney Int. 2006 Nov;70(10):1858-65 [17021609.001]
  • [Cites] Am J Kidney Dis. 1997 Apr;29(4):496-502 [9100037.001]
  • [Cites] Nephrol Dial Transplant. 2006 Aug;21(8):2217-24 [16595583.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):416-9 [17275288.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Sep;283(3):F367-76 [12167586.001]
  • [Cites] N Engl J Med. 2008 Aug 7;359(6):584-92 [18687639.001]
  • [Cites] Nephrol Dial Transplant. 2008 Nov;23(11):3479-84 [18556746.001]
  • [Cites] J Am Soc Nephrol. 2004 Aug;15(8):2208-18 [15284307.001]
  • [Cites] Pediatr Nephrol. 2008 Oct;23(10):1823-9 [18504621.001]
  • [Cites] J Bone Miner Res. 2007 Jun;22(6):860-6 [17352647.001]
  • [Cites] J Am Soc Nephrol. 2008 Jun;19(6):1239-46 [18337484.001]
  • [Cites] Am J Med Sci. 1999 Jun;317(6):370-6 [10372836.001]
  • [Cites] Circulation. 2008 Jan 29;117(4):503-11 [18180395.001]
  • [Cites] NDT Plus. 2008 Jan;1(Suppl 1):i2-i6 [25983952.001]
  • [Cites] Am J Clin Nutr. 2008 Aug;88(2):529S-533S [18689395.001]
  • [Cites] Semin Dial. 2007 Jul-Aug;20(4):337-41 [17635825.001]
  • (PMID = 20151157.001).
  • [ISSN] 1432-198X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Chelating Agents; 0 / Ergocalciferols; 0 / Naphthalenes; 0 / Phosphates; 0 / Polyamines; 0 / Receptors, Calcitriol; 0 / Receptors, Calcium-Sensing; 1K860WSG25 / Cinacalcet Hydrochloride; 6702D36OG5 / paricalcitol; 9YCX42I8IU / Sevelamer; SY7Q814VUP / Calcium
  • [Number-of-references] 89
  •  go-up   go-down


41. Tokumoto M, Taniguchi M: [The mechanisms of parathyroid hyperplasia and its regression]. Clin Calcium; 2007 May;17(5):665-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The mechanisms of parathyroid hyperplasia and its regression].
  • Parathyroid gland (PTG) is a unique endocrine organ in which the quiescent glandular cells begin to proliferate in the progressive course of renal failure, leading to secondary hypereparathyroidism (SHPT).
  • SHPT is characterized by continuous over-secretion of parathyroid hormone (PTH) and parathyroid hyperplasia, and the major contributing factors are a deficiency of active vitamin D, hypocalcemia and phosphate retention.
  • Many experimental and human studies have revealed that the down-regulations of vitamin D receptor (VDR), calcium (Ca) -sensing receptor (CaSR), and retinoid X receptor (RXR) in parathyroid hyperplasia of SHPT, especially nodular hyperplasia, which is a severe form of hyperplasia.
  • These also contribute to progression of parathyroid hyperplasia.
  • Recently, mechanisms by which active vitamin D and Ca regulate parathyroid hyperplasia via their receptors have been clarified.
  • In this paper, we review mechanisms for progression of parathyroid hyperplasia and the possibility for regression of parathyroid hyperplasia.
  • [MeSH-major] Parathyroid Glands / pathology

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17470994.001).
  • [ISSN] 0917-5857
  • [Journal-full-title] Clinical calcium
  • [ISO-abbreviation] Clin Calcium
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 1406-16-2 / Vitamin D; SY7Q814VUP / Calcium
  • [Number-of-references] 42
  •  go-up   go-down


42. Lew JI, Rivera M, Irvin GL 3rd, Solorzano CC: Operative failure in the era of focused parathyroidectomy: a contemporary series of 845 patients. Arch Surg; 2010 Jul;145(7):628-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HYPOTHESIS: Focused parathyroidectomy guided by intraoperative parathyroid hormone monitoring (IPM) may lead to higher failure rates because of missed multiglandular disease.
  • MAIN OUTCOME MEASURES: Parathyroid hormone dynamics and perioperative data were analyzed for factors affecting outcome.
  • Operative failure was defined as hypercalcemia with elevated parathyroid hormone levels within 6 months after parathyroidectomy.
  • The major cause of operative failure was the surgeon's inability to find the abnormal parathyroid gland (16 of 21 patients [76.2%]).
  • CONCLUSION: Inability of the surgeon to find the abnormal parathyroid gland-not missed multiglandular disease-is the main cause of operative failure in focused parathyroidectomy guided by IPM.
  • [MeSH-major] Biomarkers, Tumor / blood. Hypercalcemia / diagnosis. Hyperparathyroidism, Primary / surgery. Monitoring, Intraoperative / methods. Parathyroid Hormone / blood. Parathyroidectomy / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20644124.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Parathyroid Hormone
  •  go-up   go-down


43. Tonelli F, Marcucci T, Fratini G, Tommasi MS, Falchetti A, Brandi ML: Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg; 2007 Dec;246(6):1075-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1?
  • OBJECTIVE: The aim of the present report is to describe the results obtained with total parathyroidectomy (TPTX) guided by rapid intraoperative parathyroid hormone (PTH) evaluation, followed by immediate parathyroid autograft with fresh tissue.
  • SUMMARY BACKGROUND DATA: Surgery for hyperparathyroidism (HPT) in multiple endocrine neoplasia type 1 (MEN1) is performed with various surgical approaches.
  • Forty-five patients underwent TPTX as the first surgical procedure, whereas for 6 patients, a parathyroid operation was the second surgical procedure.
  • PTH intraoperative values less than 10 pg/mL, at the end of the surgery, were indicative for reimplantation of a few fragments ( approximately 7) of fresh parathyroid tissue in the brachioradial muscle of the forearm.
  • Parathyroid autograft was performed in all patients, except 3 in whom the fourth parathyroid gland was not found.
  • [MeSH-major] Hyperparathyroidism / surgery. Multiple Endocrine Neoplasia Type 1 / complications. Parathyroid Neoplasms / complications. Parathyroidectomy / methods


44. Spasovski G: New aspects of treatment of renal bone disease in dialysis patients. Prilozi; 2007 Jul;28(1):205-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The second option for stimulation of parathyroid gland activity and bone turnover is the lowering of the dialysate calcium concentration.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17932468.001).
  • [ISSN] 0351-3254
  • [Journal-full-title] Prilozi
  • [ISO-abbreviation] Prilozi
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Phosphates; SY7Q814VUP / Calcium
  • [Number-of-references] 35
  •  go-up   go-down


45. Shalhoub V, Shatzen E, Henley C, Boedigheimer M, McNinch J, Manoukian R, Damore M, Fitzpatrick D, Haas K, Twomey B, Kiaei P, Ward S, Lacey DL, Martin D: Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols. Calcif Tissue Int; 2006 Dec;79(6):431-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, calcimimetics, by binding to the parathyroid gland calcium-sensing receptors, reduce serum parathyroid hormone, calcium, phosphorus, and the calcium-phosphorus product.

  • Hazardous Substances Data Bank. PARICALCITOL .
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17171500.001).
  • [ISSN] 0171-967X
  • [Journal-full-title] Calcified tissue international
  • [ISO-abbreviation] Calcif. Tissue Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aniline Compounds; 0 / Drug Combinations; 0 / Ergocalciferols; 0 / Glycerophosphates; 0 / N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine; 0 / Receptors, Calcitriol; 0 / Receptors, Calcium-Sensing; 0 / Wnt Proteins; 27YLU75U4W / Phosphorus; 6702D36OG5 / paricalcitol; EC 3.1.3.1 / Alkaline Phosphatase; FXC9231JVH / Calcitriol; SY7Q814VUP / Calcium
  •  go-up   go-down


46. de Francisco AL, Piñera C: Parathyroid gland: cinacalcet-can it control hypercalcemia? Nat Rev Endocrinol; 2010 Jan;6(1):15-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parathyroid gland: cinacalcet-can it control hypercalcemia?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010966.001).
  • [ISSN] 1759-5037
  • [Journal-full-title] Nature reviews. Endocrinology
  • [ISO-abbreviation] Nat Rev Endocrinol
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Naphthalenes; 0 / Receptors, Calcium-Sensing; 1K860WSG25 / Cinacalcet Hydrochloride; 9007-49-2 / DNA
  •  go-up   go-down


47. Owens BB: A review of primary hyperparathyroidism. J Infus Nurs; 2009 Mar-Apr;32(2):87-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary hyperparathyroidism is the inappropriate secretion of parathyroid hormone and is the most common cause of hypercalcemia.
  • Primary hyperparathyroidism can be treated with medication and long-term monitoring; however, surgical removal of the affected parathyroid gland is the definitive treatment.
  • Rarely occurring, parathyroid crisis must be treated promptly to prevent deleterious effects to the patient.
  • The patient experiencing parathyroid crisis benefits from the infusion nurse's knowledge of drug and fluid therapies and expertise in peripheral access.
  • [MeSH-major] Hyperparathyroidism, Primary / diagnosis. Hyperparathyroidism, Primary / physiopathology

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289922.001).
  • [ISSN] 1539-0667
  • [Journal-full-title] Journal of infusion nursing : the official publication of the Infusion Nurses Society
  • [ISO-abbreviation] J Infus Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


48. Oh SY, Kim S, Eskandar Y, Kim DW, Krynyckyi BR, Machac J, Inabnet WB 3rd, Kim CK: Appearance of intrathymic parathyroid adenomas on pinhole sestamibi parathyroid imaging. Clin Nucl Med; 2006 Jun;31(6):325-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appearance of intrathymic parathyroid adenomas on pinhole sestamibi parathyroid imaging.
  • OBJECTIVES: Ectopic inferior parathyroid adenomas (PAs) are frequently located in the anterior mediastinum, quite often in the thymus gland.
  • METHODS: We retrospectively reviewed sestamibi pinhole parathyroid imaging performed on 163 patients with primary hyperparathyroidism and final diagnoses established by surgery, histology, intraoperative PTH monitoring, and clinical follow up.
  • Of the 93 foci in group A, there were 80 normally situated inferior PA, 6 descended superior PA, 3 intrathyroidal PA, one hyperplastic parathyroid gland, one thyroid adenoma, one unidentified, and one intrathymic PA.
  • CONCLUSION: Focal increased activity completely separated from the lower pole of thyroid (regardless of the distance of separation) on sestamibi pinhole images indicates a high probability of intrathymic parathyroid adenoma.
  • [MeSH-major] Adenoma / radionuclide imaging. Parathyroid Neoplasms / radionuclide imaging. Technetium Tc 99m Sestamibi. Thymus Neoplasms / radionuclide imaging. Thymus Neoplasms / secondary. Tomography, Emission-Computed, Single-Photon / methods

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16714889.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


49. Zhang CX, Weber BV, Thammavong J, Grover TA, Wells DS: Identification of carboxyl-terminal peptide fragments of parathyroid hormone in human plasma at low-picomolar levels by mass spectrometry. Anal Chem; 2006 Mar 1;78(5):1636-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of carboxyl-terminal peptide fragments of parathyroid hormone in human plasma at low-picomolar levels by mass spectrometry.
  • For decades, researchers have tried to identify the primary structures of circulating carboxyl-terminal parathyroid hormone (C-PTH) peptide fragments that may be present at only picomolar levels in human plasma.
  • This newly developed analytical capability should greatly enhance the understanding of PTH metabolism and parathyroid gland function.
  • [MeSH-major] Mass Spectrometry / methods. Parathyroid Hormone / analysis. Peptide Fragments / analysis

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16503617.001).
  • [ISSN] 0003-2700
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 0 / Peptide Fragments
  •  go-up   go-down


50. Tanaka M, Itoh K, Matsushita K, Matsushita K, Fujii H, Fukagawa M: Normalization of reversed bio-intact-PTH(1-84)/intact-PTH ratio after parathyroidectomy in a patient with severe secondary hyperparathyroidism. Clin Nephrol; 2005 Jul;64(1):69-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since 2003, he was found to have high plasma intact-PTH concentrations and two swollen parathyroid glands in the neck.
  • Recently, a few patients with parathyroid carcinoma have been found to have higher (1-84)-PTH concentrations than intact-PTH concentrations with abnormally high (1-84)-PTH/intact-PTH ratio.
  • We speculate that the resected parathyroid gland in our patient might have produced a new molecular form of PTH that was less well detected by the conventional intact-PTH assay.
  • [MeSH-major] Hyperparathyroidism, Secondary / blood. Hyperparathyroidism, Secondary / surgery. Parathyroid Hormone / blood

  • Genetic Alliance. consumer health - Hyperparathyroidism 1.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16047648.001).
  • [ISSN] 0301-0430
  • [Journal-full-title] Clinical nephrology
  • [ISO-abbreviation] Clin. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Parathyroid Hormone
  •  go-up   go-down


51. Canaff L, Zhou X, Mosesova I, Cole DE, Hendy GN: Glial cells missing-2 (GCM2) transactivates the calcium-sensing receptor gene: effect of a dominant-negative GCM2 mutant associated with autosomal dominant hypoparathyroidism. Hum Mutat; 2009 Jan;30(1):85-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glial cells missing-2 (GCM2) is a transcription factor expressed in the parathyroid hormone (PTH)-secreting cells of the parathyroid gland and is essential for their development.
  • Here, we show that both promoters (P1 and P2) of the calcium-sensing receptor (CASR) gene, a differentiation marker for the parathyroid gland, are transactivated by wild-type GCM2.

  • Genetic Alliance. consumer health - Hypoparathyroidism.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 18712808.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CASR protein, human; 0 / GCM2 protein, human; 0 / Nuclear Proteins; 0 / Receptors, Calcium-Sensing; 0 / Transcription Factors
  •  go-up   go-down


52. Goo T, Akiba Y, Kaunitz JD: Mechanisms of intragastric pH sensing. Curr Gastroenterol Rep; 2010 Dec;12(6):465-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The calcium-sensing receptor (CaSR), first described in the parathyroid gland but expressed on gastric G cells, is a logical candidate for the gastric acid sensor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1999 Nov;104(10):1383-91 [10562300.001]
  • [Cites] J Clin Invest. 1999 Nov;104(10):1341-2 [10562295.001]
  • [Cites] J Biol Chem. 2001 Oct 26;276(43):39549-52 [11507103.001]
  • [Cites] Neurogastroenterol Motil. 2002 Oct;14(5):459-75 [12358674.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1410-8 [14598257.001]
  • [Cites] J Biol Chem. 2004 Sep 3;279(36):37241-9 [15201280.001]
  • [Cites] Gastroenterology. 1973 Jun;64(6):1168-84 [4574679.001]
  • [Cites] Gastroenterology. 1975 Jan;68(1):1-7 [234900.001]
  • [Cites] J Clin Invest. 1975 Mar;55(3):462-8 [1167869.001]
  • [Cites] J Clin Invest. 1976 Sep;58(3):623-31 [956391.001]
  • [Cites] Gut. 1977 Jun;18(6):442-8 [873325.001]
  • [Cites] N Engl J Med. 1978 Jan 5;298(1):27-9 [618447.001]
  • [Cites] Gut. 1978 Sep;19(9):798-801 [710969.001]
  • [Cites] Gastroenterology. 1990 Jul;99(1):36-44 [1971610.001]
  • [Cites] Am J Physiol. 1991 Nov;261(5 Pt 1):G885-9 [1683168.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):244-50 [8093704.001]
  • [Cites] Nature. 1993 Dec 9;366(6455):575-80 [8255296.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):701-6 [7657098.001]
  • [Cites] J Clin Invest. 1997 May 15;99(10):2328-33 [9153273.001]
  • [Cites] Regul Pept. 1998 Feb 2;73(2):75-82 [9533810.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):436-41 [10201375.001]
  • [Cites] Am J Physiol. 1999 Sep;277(3 Pt 1):G662-70 [10484392.001]
  • [Cites] Acta Physiol Scand. 1964 May-Jun;61:55-64 [14168047.001]
  • [Cites] J Neurosci. 2005 Mar 9;25(10):2617-27 [15758172.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Oct;289(4):G664-9 [15961860.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Dec;289(6):G1084-90 [16109841.001]
  • [Cites] Pflugers Arch. 2006 Mar;451(6):738-48 [16308696.001]
  • [Cites] Pain. 2008 Feb;134(3):245-53 [17531389.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G130-8 [17975130.001]
  • [Cites] Gastroenterology. 2008 Jun;134(7):1842-60 [18474247.001]
  • [Cites] Osteoporos Int. 2009 Jan;20(1):71-8 [18536954.001]
  • [Cites] Neurogastroenterol Motil. 2010 Jun;22(6):680-7 [20100279.001]
  • [Cites] Gastroenterology. 2001 Apr;120(5):1128-39 [11266377.001]
  • (PMID = 20938760.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK054221; United States / PHS HHS / / R01 543221
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Gastrins; 0 / Receptors, Calcium-Sensing
  • [Other-IDs] NLM/ PMC2974196
  •  go-up   go-down


53. Târcoveanu E, Niculescu D, Cotea E, Moldovanu R, Vasilescu A, Crumpei F, Zbranca E, Zugun F, Rusu V, Ferariu D: [Parathyroid glands involvement in multiple endocrine neoplasia]. Rev Med Chir Soc Med Nat Iasi; 2009 Apr-Jun;113(2):482-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Parathyroid glands involvement in multiple endocrine neoplasia].
  • Parathyroid gland involvement is usually noted in Multiple Endocrine Neoplasia (MEN) type I and type II.
  • Parathyroid glands tumor associated with endocrine pancreatic tumor, as well as pituitary tumors is the typical pattern of MEN I.
  • The parathyroid gland is the most frequent abnormality in MEN I.
  • CASES REPORTS: We presented five cases with MEN I and parathyroid glands involvement.
  • In three cases with young ages (28-33 years old) and familial setting, the MEN I syndrome was "complete" (parathyroid adenoma, gastrinoma or insulinoma and pituitary adenoma--prolactinoma or GH-secreting tumors), and, in the other two cases, with 57 and 68 years old respectively, the MEN I syndrome was "incomplete" with parathyroid glands and pituitary gland involvement.
  • The cases with gastrinomas were operated in emergency for complication of peptic ulcer (perforation associated with peritonitis and gastro-intestinal bleeding); then the pancreatic tumors were diagnosed and left pancreatectomy with spleen preservation and respectively, tumor resection have been performed.
  • Unfortunately one patients died due to severe endocrine disorder.
  • The imagistic and laboratory test diagnosed a tumor situated into the pancreatic body, and an parathyroid adenoma.
  • The resection of pancreatic tumor associated with resection of the parathyroid adenoma, in the same time, were performed.
  • The other two cases with "incomplete" MEN were older then the first patients, and were diagnosed with hyperparathyrodism and pituitary gland tumor.
  • The resection of parathyroid gland adenoma has been performed in both cases, with uneventful postoperative course.
  • CONCLUSIONS: The parathyroid glands involvement in MEN is common.
  • There are two kinds of MEN associated with parathyroid gland involvement: the "complete" form, especially in young patients, with diffuse involvement of the parathyroid glands, and the subtotal parathyroidy is the best choice, and the "incomplete" form, especially in elderly, with the involvement of a single parathyroid gland; in this way, the resection of the adenoma associated with biopsy from the other parathyroid gland is the best approach.
  • [MeSH-major] Adenoma / surgery. Gastrinoma / surgery. Insulinoma / surgery. Multiple Endocrine Neoplasia Type 1 / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery. Parathyroid Neoplasms / surgery. Parathyroidectomy
  • [MeSH-minor] Adult. Aged. Fatal Outcome. Female. Humans. Hyperparathyroidism, Secondary / diagnosis. Hyperparathyroidism, Secondary / etiology. Male. Middle Aged. Multiple Endocrine Neoplasia / surgery. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / surgery. Prolactinoma / diagnosis. Prolactinoma / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495355.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


54. Robertson A, Mansberg R, Mansberg V, Van der Wall H, Hooper M: Tumor-induced osteomalacia: a case of diagnostic dilemma. Clin Nucl Med; 2007 Aug;32(8):631-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-induced osteomalacia: a case of diagnostic dilemma.
  • Tumor-induced osteomalacia is typically caused by benign mesenchymal tumors of vascular or skeletal origin.
  • Localization and resection of the FGF-23-secreting tumor offers the best chance of cure.
  • Biochemical investigations showed hypophosphatemia, hyperphosphaturia, and increased alkaline phosphatase, suggesting the presence of an FGF-23-secreting tumor.
  • Thyroid and parathyroid scintigraphy were performed and showed separate areas of focally increased tracer uptake in the neck.
  • The patient underwent octreotide scintigraphy to localize an alternative site of tumor.
  • Histopathology showed a papillary carcinoma of the thyroid, a parathyroid adenoma, and an adrenal adenoma.
  • [MeSH-major] Fractures, Bone / diagnosis. Fractures, Spontaneous / diagnosis. Neoplasms, Multiple Primary / complications. Neoplasms, Multiple Primary / diagnosis. Octreotide. Osteomalacia / diagnosis. Osteomalacia / etiology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Radiopharmaceuticals. Whole Body Imaging

  • Genetic Alliance. consumer health - Osteomalacia.
  • MedlinePlus Health Information. consumer health - Fractures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667438.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; RWM8CCW8GP / Octreotide
  •  go-up   go-down


55. Pulvirenti D, Campagna A, Ignaccolo L, Giustolisi N, Costa V: [Medical-surgical integrated approach in the treatment of non-paraneoplasic hyperparathyroidism: our experience]. Clin Ter; 2009;160(1):21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Approccio integrato medico-chirurgico nel trattamento dell'iperparatiroidismonon-paraneoplastico: la nostra esperienza.
  • OBJECTIVE: Hyperparathyroidism is a generalized alteration of calcium, phosphorus and bone metabolism due to an increased secretion of parathyroid hormone (PTH).
  • In addition to the paraneoplastic ectopic type, we can distinguish three eutopic types of hyperparathyroidism, i.e., the primary form, mostly due to a benign or malignant tumor of parathyroid gland, the secondary form, typical of kidney disease and tertiary form, due to the progression of secondary forms.
  • CONCLUSIONS: A correct approach to a non-paraneoplastic hyper-parathyroid patient need of an integration of both current medical and surgical options.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19290408.001).
  • [ISSN] 1972-6007
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


56. Haffner D, Fischer DC: Bone cell biology and pediatric renal osteodystrophy. Minerva Pediatr; 2010 Jun;62(3):273-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with chronic kidney disease (CKD) show a broad spectrum of clinical symptoms intimately related to the disturbed mineral and bone metabolism and summarized as CKD-mineral-bone disorder (CKD-MBD).
  • In other words, the complex interplay between kidney, skeleton, parathyroid gland, the intestine and the cardiovasculature is severely disturbed in CKD.

  • Genetic Alliance. consumer health - Renal osteodystrophy.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20467380.001).
  • [ISSN] 0026-4946
  • [Journal-full-title] Minerva pediatrica
  • [ISO-abbreviation] Minerva Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Phosphates; SY7Q814VUP / Calcium
  • [Number-of-references] 73
  •  go-up   go-down


57. Wesseling-Perry K, Salusky IB: Is replacement therapy with nutritional and active forms of vitamin D required in chronic kidney disease mineral and bone disorder? Curr Opin Nephrol Hypertens; 2009 Jul;18(4):308-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is replacement therapy with nutritional and active forms of vitamin D required in chronic kidney disease mineral and bone disorder?
  • RECENT FINDINGS: Both 25(OH)vitamin D and 1,25(OH)2vitamin D therapy have actions on parathyroid gland, cardiac, bone, and immune system function.
  • [MeSH-minor] Animals. Chronic Disease. Humans. Organ Specificity. Parathyroid Hormone / blood. Vitamin D Deficiency / drug therapy

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19458529.001).
  • [ISSN] 1473-6543
  • [Journal-full-title] Current opinion in nephrology and hypertension
  • [ISO-abbreviation] Curr. Opin. Nephrol. Hypertens.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 1406-16-2 / Vitamin D; 64719-49-9 / 25-hydroxyvitamin D; FXC9231JVH / Calcitriol
  • [Number-of-references] 90
  •  go-up   go-down


58. Pulvirenti D, Aikaterini T, Campagna A, Ignaccolo L, Giustolisi N, Costa E: [Medical-surgical integrated approach in the treatment of non-paraneoplasic hyperparathyroidism: our experience]. Clin Ter; 2008 Sep-Oct;159(5):307-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Approccio integrato medico-chirurgico nel trattamento dell'iperparatiroidismonon-paraneoplastico: la nostra esperienza.
  • OBJECTIVE: Hyperparathyroidism is a generalized alteration of calcium, phosphorus and bone metabolism due to an increased secretion of parathyroid hormone (PTH).
  • In addition to the paraneoplastic ectopic type, we can distinguish three eutopic types of hyperparathyroidism, i.e., the primary form, mostly due to a benign or malignant tumor of parathyroid gland, the secondary form, typical of kidney disease and tertiary form, due to the progression of secondary forms.
  • CONCLUSIONS: A correct approach to a non-paraneoplastic hyper-parathyroid patient need of an integration of both current medical and surgical options.
  • [MeSH-minor] Adult. Aged. Bone Density Conservation Agents / therapeutic use. Calcium / blood. Calcium / therapeutic use. Diphosphates / therapeutic use. Diuretics / therapeutic use. Drug Therapy, Combination. Female. Humans. Hyperparathyroidism, Primary / drug therapy. Hyperparathyroidism, Primary / surgery. Hyperparathyroidism, Secondary / drug therapy. Hyperparathyroidism, Secondary / surgery. Male. Middle Aged. Parathyroid Hormone / blood. Parathyroid Neoplasms / drug therapy. Parathyroid Neoplasms / surgery. Postoperative Care / methods. Preoperative Care / methods. Retrospective Studies. Treatment Outcome. Vitamin D / therapeutic use

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18998031.001).
  • [ISSN] 1972-6007
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphates; 0 / Diuretics; 0 / Parathyroid Hormone; 1406-16-2 / Vitamin D; SY7Q814VUP / Calcium
  •  go-up   go-down


59. Brown AJ, Slatopolsky E: Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol Aspects Med; 2008 Dec;29(6):433-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The vitamin D endocrine system plays a central role in mineral ion homeostasis through the actions of the vitamin D hormone, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], on the intestine, bone, parathyroid gland, and kidney.

  • MedlinePlus Health Information. consumer health - Vitamin D.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18554710.001).
  • [ISSN] 0098-2997
  • [Journal-full-title] Molecular aspects of medicine
  • [ISO-abbreviation] Mol. Aspects Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Calcitriol; 0 / Vitamin D-Binding Protein; 1406-16-2 / Vitamin D
  • [Number-of-references] 203
  •  go-up   go-down


60. Norman J, Politz D: Measuring individual parathyroid gland hormone production in real-time during radioguided parathyroidectomy. Experience in over 8,000 operations. Minerva Endocrinol; 2008 Sep;33(3):147-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measuring individual parathyroid gland hormone production in real-time during radioguided parathyroidectomy. Experience in over 8,000 operations.
  • AIM: Determining the physiologic activity (hormone production) of individual parathyroid glands by measuring their contained radioactivity is extremely accurate and provides tremendous guidance during parathyroidectomy.
  • Ex-vivo measures of parathyroid glands, thyroid nodules, lymph nodes, thymus, and fat were obtained from all patients, constituting over 42,000 specimens.
  • RESULTS: Parathyroid glands occur in three distinct groups according to their hormone production which very accurately indicates the type of pathology present.
  • CONCLUSIONS: Measures of sequestered radioactivity is an extremely accurate estimate of individual parathyroid gland hormone production allowing near 100% distinction between normal, hyperplasic, and adenomatous glands as well as distinguishing parathyroids from other neck tissues (fat, lymph nodes, thyroid).
  • This instantaneous measure can eliminate frozen sections and parathyroid hormone assays in nearly all patients undergoing parathyroid surgery, providing insight that allows the operation to progress rapidly.
  • [MeSH-major] Adenoma / secretion. Computer Systems. Parathyroid Glands / secretion. Parathyroid Hormone / biosynthesis. Parathyroid Neoplasms / secretion. Parathyroidectomy / methods. Surgery, Computer-Assisted / methods

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18846022.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / PTH protein, human; 0 / Parathyroid Hormone; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi; SY7Q814VUP / Calcium
  •  go-up   go-down


61. Mårtensson UE, Bristulf J, Owman C, Olde B: The mouse chemerin receptor gene, mcmklr1, utilizes alternative promoters for transcription and is regulated by all-trans retinoic acid. Gene; 2005 Apr 25;350(1):65-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CMKLR1 (chemoattractant-like receptor 1) is a G-protein-coupled receptor implicated in cartilage and bone development and is expressed in organs like the parathyroid gland, brain, and lung.

  • Guide to Pharmacology. gene/protein/disease-specific - chemerin receptor - data and references .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792532.001).
  • [ISSN] 0378-1119
  • [Journal-full-title] Gene
  • [ISO-abbreviation] Gene
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY681348
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CMKLR1 protein, mouse; 0 / Nuclear Proteins; 0 / Oligonucleotide Probes; 0 / Protein Isoforms; 0 / Receptors, G-Protein-Coupled; 0 / Recombinant Fusion Proteins; 5688UTC01R / Tretinoin; 63231-63-0 / RNA; EC 1.13.12.- / Luciferases
  •  go-up   go-down


62. Rangoonwala SP, Suryawanshi SA, Pandey AK: Responses of serum calcium and inorganic phosphate levels as well as parathyroid gland and calcitonin producing C cells of Rattus norvegicus to Mipcin administration. J Environ Biol; 2007 Apr;28(2 Suppl):475-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Responses of serum calcium and inorganic phosphate levels as well as parathyroid gland and calcitonin producing C cells of Rattus norvegicus to Mipcin administration.
  • Parathyroid chief cells of the experimental rats exhibited degranulation, vacuolation, loss of secretory (hormone) granules and lipid droplets, decreased chromatin in nuclei and damages in the endoplasmic reticulum as well as cristae of mitochondria at 14 days of the treatment.
  • Not much of changes could be seen in the oxyphil cells of parathyroid as well as thyroid C cells of the Mipcin-treated rats.
  • [MeSH-major] Calcium / blood. Carbamates / toxicity. Hypocalcemia / chemically induced. Insecticides / toxicity. Parathyroid Glands / drug effects
  • [MeSH-minor] Animals. Calcitonin / metabolism. Male. Phosphates / blood. Rats. Thyroid Gland / drug effects. Thyroid Gland / ultrastructure

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. Calcitonin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929768.001).
  • [ISSN] 0254-8704
  • [Journal-full-title] Journal of environmental biology
  • [ISO-abbreviation] J Environ Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / 2-isopropylphenyl-N-methylcarbamate; 0 / Carbamates; 0 / Insecticides; 0 / Phosphates; 9007-12-9 / Calcitonin; SY7Q814VUP / Calcium
  •  go-up   go-down


63. Schaan BD, Huber J, Leite JC, Kiss A: Cardiac surgery unmasks latent hypoparathyroidism in a child with the 22q11.2 deletion syndrome. J Pediatr Endocrinol Metab; 2006 Jul;19(7):943-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 22q11.2 deletion syndrome is a developmental field defect of the third and fourth pharyngeal pouches characterized by a spectrum of thymic and parathyroid gland abnormalities and conotruncal cardiac defects.
  • Latent hypoparathyroidism, defined as normocalcaemia at rest but reduced ability to secrete parathyroid hormone (PTH) in response to pharmacologically evoked hypocalcaemia, is found in 30-50% of people with this syndrome.
  • The clinical picture led us to the diagnosis of 22q11.2 deletion syndrome.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 22. Hypoparathyroidism / diagnosis. Tetralogy of Fallot / genetics. Tetralogy of Fallot / surgery


64. Kakuta T, Fukagawa M, Kitaoka M, Koiwa F, Onoda N, Tominaga Y, Akizawa T, Kurokawa K, Japanese Society for Parathyroid Intervention: Percutaneous ethanol injection therapy for advanced renal hyperparathyroidism in Japan: 2004 survey by the Japanese Society for Parathyroid Intervention. NDT Plus; 2008 Aug;1(Suppl 3):iii21-iii25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous ethanol injection therapy for advanced renal hyperparathyroidism in Japan: 2004 survey by the Japanese Society for Parathyroid Intervention.
  • Background. Marked hyperplasia of the parathyroid gland (PTG) is a characteristic feature of severe hyperparathyroidism in patients under chronic haemodialysis treatment.
  • The Japanese Society for Parathyroid Intervention surveyed its membership in 2004 to revise the guidelines for the use of PEIT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25983968.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4421128
  • [Keywords] NOTNLM ; haemodialysis / nodular hyperplasia / parathyroidectomy (PTx) / percutaneous ethanol injection therapy (PEIT) / secondary hyperparathyroidism (SHPT)
  •  go-up   go-down


65. Sankarasubbaiyan S, Abraham G, Soundararajan P, Chandrasekaran V, Padma G: Parathyroid hormone and biochemical profile in chronic kidney disease patients in South India. Hemodial Int; 2005 Jan;9(1):63-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parathyroid hormone and biochemical profile in chronic kidney disease patients in South India.
  • Intact parathyroid hormone (PTH) level was 124.6 +/- 174.9 pg/mL and less than twice normal in 69.5% of patients.
  • Etiology remains uncertain but differences in dietary intake, tropical climate, vitamin D activation, vitamin D receptor polymorphism, parathyroid gland sensitivity, and PTH target organ sensitivity may account for the difference in pattern in bone disease.
  • [MeSH-major] Kidney Failure, Chronic / blood. Parathyroid Hormone / blood. Peritoneal Dialysis. Renal Osteodystrophy / blood

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16191055.001).
  • [ISSN] 1492-7535
  • [Journal-full-title] Hemodialysis international. International Symposium on Home Hemodialysis
  • [ISO-abbreviation] Hemodial Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Parathyroid Hormone
  •  go-up   go-down


66. Fakhran S, Branstetter BF 4th, Pryma DA: Parathyroid imaging. Neuroimaging Clin N Am; 2008 Aug;18(3):537-49, ix
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parathyroid imaging.
  • The most common indication for parathyroid imaging is hyperparathyroidism, which is caused by a solitary parathyroid adenoma in most patients.
  • The primary function of parathyroid imaging is localization of the abnormal parathyroid gland, enabling the surgeon to pursue a minimally invasive resection.
  • In cases of suspected parathyroid carcinoma, preoperative CT or MR imaging is recommended for surgical planning.
  • [MeSH-major] Parathyroid Diseases / diagnosis. Parathyroid Glands. Parathyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Parathyroid Disorders.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656034.001).
  • [ISSN] 1052-5149
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


67. Butte JM, Montero PH, Solar A, Torres J, Olmos PR, Goñi I, Quintana JC, Martínez J, Llanos O: Cervical metastases of glucagonoma in a patient with multiple endocrine neoplasia type 1: report of a case. Surg Today; 2008;38(12):1137-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical metastases of glucagonoma in a patient with multiple endocrine neoplasia type 1: report of a case.
  • Multiple endocrine neoplasia type 1 (MEN 1) is a syndrome characterized by tumors of the parathyroid glands, pancreatic islet cells, duodenum, and pituitary gland.
  • Thus, we performed a distal pancreatectomy with bilateral cervical dissection and parathyroid gland resection.
  • The resected parathyroid glands had normal structure, suggesting parathyroid hyperplasia.
  • A pancreatoduodenectomy was performed and histopathological examination revealed nine nonfunctioning endocrine tumors in the pancreas, one tumor in the duodenal wall, and metastases in two peripancreatic lymph nodes.
  • [MeSH-major] Glucagonoma / pathology. Multiple Endocrine Neoplasia Type 1 / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Cholecystectomy. Duodenal Neoplasms / pathology. Duodenal Neoplasms / secondary. Female. Humans. Hyperplasia. Hypoglycemia / etiology. Immunohistochemistry. Lymphatic Metastasis. Neck. Pancreatectomy. Pancreaticoduodenectomy. Parathyroid Glands / pathology. Parathyroid Glands / surgery. Splenectomy


68. Shiizaki K, Hayakawa N, Imazeki I, Hatamura I, Okada T, Negi S, Sakaguchi T, Shigematsu T, Akizawa T: Binding of highly concentrated maxacalcitol to the nuclear vitamin D receptors of parathyroid cells. Nephrol Dial Transplant; 2007 Apr;22(4):1078-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Binding of highly concentrated maxacalcitol to the nuclear vitamin D receptors of parathyroid cells.
  • BACKGROUND: Injection of maxacalcitol (OCT) directly into the parathyroid gland (PTG) is a clinically safe and effective treatment for advanced secondary hyperparathyroidism (A-SHPT) resistant to conventional medical treatment.
  • In the present study, the degree of nuclear localization of directly injected OCT in parathyroid cells (PTC) was investigated by microautoradiography (mARG) in a model of A-SHPT.
  • The bilateral PTG were surgically exposed and only the left gland were directly injected with 3H-OCT (DI-3H-OCT).
  • RESULTS: Peak radioactivity levels in the directly injected and intact PTG occured immediately and 1 h, respectively, after DI-3H-OCT, and the difference was about 50-fold higher in the treated gland.
  • The of mARG showed a marked concentration of silver grains in the nuclei of PTC in the gland treated with DI-3H-OCT and that concentration was significantly suppressed by IV-1,25D3.
  • CONCLUSIONS: Direct injection of OCT into the PTG enables the administration of the highly concentrated drug for specific binding to nuclear vitamin D binding sites, including VDR of PTC, which markedly suppresses the parathyroid hormone, improves the response to calcium and vitamin D and induces apoptosis in PTC.
  • [MeSH-major] Antineoplastic Agents / metabolism. Calcitriol / analogs & derivatives. Parathyroid Glands / metabolism. Receptors, Calcitriol / metabolism
  • [MeSH-minor] Animals. Apoptosis / physiology. Calcium / pharmacology. Disease Models, Animal. Hyperparathyroidism, Secondary / drug therapy. Injections. Male. Parathyroid Hormone / physiology. Protein Binding. Rats. Rats, Sprague-Dawley. Uremia / metabolism. Vitamin D / pharmacology

  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17234669.001).
  • [ISSN] 0931-0509
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Parathyroid Hormone; 0 / Receptors, Calcitriol; 103909-75-7 / maxacalcitol; 1406-16-2 / Vitamin D; FXC9231JVH / Calcitriol; SY7Q814VUP / Calcium
  •  go-up   go-down


69. Orita H, Hatamura I, Saji F, Shibata M, Shiizaki K, Sakaguchi T, Negi S, Akizawa T: [Enhanced expression of EGFR, TGF-alpha, EGF in hyperplastic parathyroid glands in established stage of renal failure in rats]. Clin Calcium; 2005 Sep;15 Suppl 1:60-63; discussion 63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Enhanced expression of EGFR, TGF-alpha, EGF in hyperplastic parathyroid glands in established stage of renal failure in rats].
  • It was reported that the parathyroid gland hyperplasia correlated with enhanced co-expression of TGF-alpha and its receptor EGFR at early stages of renal failure.
  • [MeSH-major] Parathyroid Glands / metabolism. Parathyroid Glands / pathology. Receptor, Epidermal Growth Factor / metabolism. Renal Insufficiency / metabolism
  • [MeSH-minor] Animals. Cell Proliferation. Disease Models, Animal. Epidermal Growth Factor / metabolism. Hyperplasia / etiology. Intracellular Signaling Peptides and Proteins / pharmacology. Male. Parathyroid Hormone / blood. Phosphorus, Dietary / administration & dosage. Quinazolines / pharmacology. Rats. Rats, Sprague-Dawley. Time Factors. Transforming Growth Factor alpha / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Calcium.2006 Feb;16(2):149-52
  • (PMID = 16411340.001).
  • [ISSN] 0917-5857
  • [Journal-full-title] Clinical calcium
  • [ISO-abbreviation] Clin Calcium
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Parathyroid Hormone; 0 / Phosphorus, Dietary; 0 / Quinazolines; 0 / Transforming Growth Factor alpha; 0 / protein kinase modulator; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


70. Lignitz S, Musholt TJ, Kreft A, Engel R, Brzezinska R, Pohlenz J: Intrathyroidal thymic tissue surrounding an intrathyroidal parathyroid gland, the cause of a solitary thyroid nodule in a 6-year-old boy. Thyroid; 2008 Oct;18(10):1125-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathyroidal thymic tissue surrounding an intrathyroidal parathyroid gland, the cause of a solitary thyroid nodule in a 6-year-old boy.
  • Ectopic intrathyroidal thymic tissue is a rare occurrence; parathyroid glands sometimes occur in an intrathyroidal location, but this is uncommon.
  • A hemithyroidectomy was performed, and histological investigation revealed that the nodule consisted of ectopic intrathyroidal thymus tissue surrounding a well-defined parathyroidal gland.
  • This condition is an exceedingly rare cause of a thyroid nodule, but intrathyroidal thymic tissue should probably be included in the differential diagnosis of solitary thyroid nodules.
  • [MeSH-major] Choristoma / diagnosis. Parathyroid Glands. Thymus Gland. Thyroid Diseases / diagnosis. Thyroid Nodule / diagnosis
  • [MeSH-minor] Child. Diagnosis, Differential. Humans. Male. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18844477.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Tokumoto M, Taniguchi M, Matsuo D, Tsuruya K, Hirakata H, Iida M: [Cell proliferation of parathyroid gland in patients with progressive secondary hyperparathyroidism: Vitamin D receptor, calcium sensing receptor, and cell cycle regulation factor]. Clin Calcium; 2005 Sep;15 Suppl 1:206-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cell proliferation of parathyroid gland in patients with progressive secondary hyperparathyroidism: Vitamin D receptor, calcium sensing receptor, and cell cycle regulation factor].
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Hyperparathyroidism, Secondary / pathology. Parathyroid Glands / metabolism. Parathyroid Glands / pathology. Receptors, Calcitriol / metabolism. Receptors, Calcium-Sensing / metabolism
  • [MeSH-minor] Animals. Calcium / metabolism. Cell Proliferation. Disease Progression. Humans. Hyperplasia. Parathyroid Hormone / blood. Vitamin D / administration & dosage

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16279026.001).
  • [ISSN] 0917-5857
  • [Journal-full-title] Clinical calcium
  • [ISO-abbreviation] Clin Calcium
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Parathyroid Hormone; 0 / Receptors, Calcitriol; 0 / Receptors, Calcium-Sensing; 1406-16-2 / Vitamin D; SY7Q814VUP / Calcium
  • [Number-of-references] 70
  •  go-up   go-down


72. Kitazawa S, Kondo T, Kitazawa R: Application trials of in situ hybridization at the electron microscopic level. Neuropathology; 2005 Sep;25(3):274-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, with oligo-DNA probes specific for alternative spliced forms of parathyroid hormone-related protein mRNA, we demonstrated such forms in a hyperplastic parathyroid gland attributed to renal failure.
  • [MeSH-major] Bone Morphogenetic Proteins / genetics. In Situ Hybridization / methods. Microscopy, Electron, Transmission. Parathyroid Hormone-Related Protein / genetics. RNA, Messenger / analysis
  • [MeSH-minor] Alternative Splicing. Animals. Bone Morphogenetic Protein 3. Cell Differentiation. Cell Line. Chondrocytes / cytology. Chondrocytes / ultrastructure. Fetus. Humans. Hyperplasia / genetics. Immunohistochemistry. Mice. Parathyroid Glands / metabolism. Parathyroid Glands / ultrastructure. RNA Probes

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16193847.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / BMP3 protein, human; 0 / Bone Morphogenetic Protein 3; 0 / Bone Morphogenetic Proteins; 0 / Parathyroid Hormone-Related Protein; 0 / RNA Probes; 0 / RNA, Messenger
  •  go-up   go-down


73. Ing SW, Pelliteri PK: Diagnostic fine-needle aspiration biopsy of an intrathyroidal parathyroid gland and subsequent eucalcemia in a patient with primary hyperparathyroidism. Endocr Pract; 2008 Jan-Feb;14(1):80-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic fine-needle aspiration biopsy of an intrathyroidal parathyroid gland and subsequent eucalcemia in a patient with primary hyperparathyroidism.
  • OBJECTIVE: To present the clinical course of a patient with persistent primary hyperparathyroidism (PHPT) whose intrathyroidal parathyroid gland was diagnosed by ultrasound-guided fine-needle aspiration biopsy (FNAB).
  • METHODS: We describe the clinical course and laboratory, radiographic, and microscopic findings of a patient with persistent PHPT due to an intrathyroidal cystic parathyroid gland and review the relevant literature.
  • RESULTS: A 74-year-old man with PHPT (presenting serum calcium concentration, 16.2 mg/dL; intact parathyroid hormone [PTH] concentration, 341 pg/mL) had surgical excision of the right superior, right inferior, and left inferior parathyroid glands, but the left superior parathyroid gland remained unidentified.
  • Microscopic examination revealed parathyroid hyperplasia.
  • Reoperation with attention to the left neck failed to locate another parathyroid gland.
  • Results from FNAB of the solid component were consistent with parathyroid cells, and cystic fluid PTH concentration was greater than 1800 pg/mL.
  • CONCLUSION: Autoinfarction of the parathyroid gland and aspiration of cystic fluid may explain resolution of hypercalcemia.
  • Although PHPT due to functioning parathyroid cysts is rare, and PHPT due to cystic parathyroid hyperplasia has been described, this is the first case report of a patient with persistent PHPT due to a functional parathyroid cyst whose diagnosis by FNAB was followed by eucalcemia.
  • [MeSH-major] Calcium / blood. Choristoma / diagnosis. Hyperparathyroidism, Primary / etiology. Parathyroid Glands. Thyroid Diseases / complications. Thyroid Diseases / diagnosis

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18238745.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Naphthalenes; 1K860WSG25 / Cinacalcet Hydrochloride; SY7Q814VUP / Calcium
  •  go-up   go-down


74. Tsuruoka S, Kaneda T, Maeda A, Ioka T, Fujimura A: Dosing time-dependent variation of bone resorption by cyclosporin A in rats' femurs. Eur J Pharmacol; 2007 Jun 14;564(1-3):226-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Body weight, creatinine clearance, serum parathyroid hormone, the trough level of cyclosporin A in whole blood and urinary excretion of Ca and P were not changed by the drug at every any dosing time.
  • Increase of urine deoxypyridinoline excretion, a marker of osteoclast activity, by the drug was highest at 2 HALO and lowest at 14 HALO, however parathyroid hormone and osteocalcin concentrations after cyclosporin A treatment did not vary with dosing time.
  • Sensitivity of osteoclasts by the drug was the major mechanisms of the phenomenon, while differences in pharmacokinetics, the parathyroid gland, osteoblasts and renal handling of Ca and P did not contribute to the phenomenon.
  • [MeSH-minor] Absorptiometry, Photon. Amino Acids / urine. Animals. Body Weight / drug effects. Bone Density / drug effects. Calcium / blood. Calcium / urine. Creatinine / urine. Drug Administration Schedule. Femur / drug effects. Femur / metabolism. Male. Osteoblasts / drug effects. Osteoblasts / metabolism. Osteocalcin / blood. Osteocalcin / drug effects. Parathyroid Hormone / blood. Phosphates / blood. Phosphates / urine. Rats. Rats, Wistar

  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17362919.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Immunosuppressive Agents; 0 / Parathyroid Hormone; 0 / Phosphates; 104982-03-8 / Osteocalcin; 83HN0GTJ6D / Cyclosporine; 90032-33-0 / deoxypyridinoline; AYI8EX34EU / Creatinine; SY7Q814VUP / Calcium
  •  go-up   go-down


75. Ozcan UA, Oktay I: Assessment of parathyroid glands in hemodialysis patients by using color Doppler sonography. Eur Radiol; 2009 Nov;19(11):2750-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of parathyroid glands in hemodialysis patients by using color Doppler sonography.
  • The aim of this study was to assess the role of color and spectral Doppler ultrasound (CDU) in the evaluation of enlarged parathyroid glands in hemodialysis patients with secondary hyperparathyroidism.
  • Fourteen hemodialysis patients with elevated intact parathyroid hormone (iPTH) levels were evaluated prospectively with CDU.
  • The volume of each observed parathyroid gland and the spectral CDU data (velocities, resistance and pulsatility indices, systolic to diastolic ratio, and flow volume output (FVO)) were noted.
  • Two patients were excluded, and 27 enlarged parathyroid glands were observed in 12 patients.
  • The mean total volume of enlarged parathyroid glands per patient was 1.95 cm(3) (0.06-5.5 cm(3)).
  • Arterial supply was demonstrated in 78% (21/27) of enlarged parathyroid glands.
  • In secondary hyperparathyroidism, total volume of the visualized enlarged parathyroid glands and the total of FVOs per patient are positively correlated with iPTH levels which may help clinical management and follow-up of end-stage renal disease patients.
  • [MeSH-major] Parathyroid Glands / diagnostic imaging. Parathyroid Glands / pathology. Renal Dialysis / adverse effects. Ultrasonography, Doppler / methods
  • [MeSH-minor] Adult. Calcium / metabolism. Female. Humans. Kinetics. Male. Middle Aged. Parathyroid Hormone / metabolism. Phosphates / metabolism. Prospective Studies. Radiopharmaceuticals / pharmacology. Technetium Tc 99m Sestamibi / pharmacology

  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2000 Feb;214(2):393-402 [10671586.001]
  • [Cites] Nephrol Dial Transplant. 2002 Sep;17(9):1553-7 [12198204.001]
  • [Cites] J Ultrasound Med. 1994 Apr;13(4):303-8 [7932996.001]
  • [Cites] Head Neck. 2000 Aug;22(5):509-12 [10897112.001]
  • [Cites] Adv Ren Replace Ther. 2002 Jul;9(3):159-67 [12203197.001]
  • [Cites] J Ultrasound Med. 1993 Nov;12 (11):673-8 [8264021.001]
  • [Cites] Kidney Int Suppl. 1999 Dec;73:S65-9 [10633467.001]
  • [Cites] Ther Apher Dial. 2008 Oct;12 (5):391-5 [18937723.001]
  • [Cites] Ther Apher Dial. 2008 Oct;12 (5):385-90 [18937722.001]
  • [Cites] Eur Radiol. 1997;7(5):721-5 [9166572.001]
  • [Cites] Radiology. 2001 Sep;220(3):631-9 [11526260.001]
  • [Cites] AJR Am J Roentgenol. 1998 Sep;171(3):819-23 [9725323.001]
  • [Cites] Eur Radiol. 1997;7(1):90-5 [9000405.001]
  • [Cites] Nephrol Dial Transplant. 2003 Jun;18 Suppl 3:iii34-7 [12771297.001]
  • [Cites] J Ultrasound Med. 2002 May;21(5):539-52; quiz 553-4 [12008817.001]
  • [Cites] Stroke. 1999 Dec;30(12 ):2692-6 [10582999.001]
  • [Cites] Nephrol Dial Transplant. 1998 Dec;13(12 ):3111-7 [9870475.001]
  • [Cites] Nephrol Dial Transplant. 2003 Jun;18 Suppl 3:iii31-3 [12771296.001]
  • [Cites] AJR Am J Roentgenol. 2002 Aug;179(2):495-502 [12130462.001]
  • [Cites] AJR Am J Roentgenol. 2002 Mar;178(3):551-6 [11856672.001]
  • [Cites] Kidney Int Suppl. 1999 Dec;73:S38-41 [10633462.001]
  • [Cites] Nephrol Dial Transplant. 2003 Jun;18 Suppl 3:ii27-30 [12771295.001]
  • [Cites] Kidney Int Suppl. 2003 Jun;(85):S101-4 [12753277.001]
  • [Cites] AJR Am J Roentgenol. 1996 Jun;166(6):1465-70 [8633466.001]
  • [Cites] Nephrol Dial Transplant. 2003 Jun;18 Suppl 3:iii23-6 [12771294.001]
  • [Cites] Radiology. 2002 Jan;222(1):103-7 [11756712.001]
  • (PMID = 19471937.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 0 / Phosphates; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi; SY7Q814VUP / Calcium
  •  go-up   go-down


76. Torres PU: Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. J Ren Nutr; 2006 Jul;16(3):253-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secondary hyperparathyroidism (SHPT) develops as a result of impaired calcium homeostasis when the failing kidneys disturb the complicated interactions between parathyroid hormone (PTH), calcium, phosphorus, and vitamin D.
  • Twelve years ago, the calcium-sensing receptor (CaR) of the parathyroid gland was first cloned and identified as the principal regulator of PTH secretion.
  • [MeSH-minor] Calcium / metabolism. Cinacalcet Hydrochloride. Humans. Hypercalcemia / drug therapy. Kidney Transplantation. Parathyroid Glands / chemistry. Parathyroid Hormone / adverse effects. Parathyroid Neoplasms / drug therapy. Phosphates / metabolism. Randomized Controlled Trials as Topic. Receptors, Calcium-Sensing / physiology. Renal Dialysis. Vitamin D / metabolism

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16825031.001).
  • [ISSN] 1532-8503
  • [Journal-full-title] Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation
  • [ISO-abbreviation] J Ren Nutr
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Naphthalenes; 0 / Parathyroid Hormone; 0 / Phosphates; 0 / Receptors, Calcium-Sensing; 1406-16-2 / Vitamin D; 1K860WSG25 / Cinacalcet Hydrochloride; SY7Q814VUP / Calcium
  • [Number-of-references] 48
  •  go-up   go-down


77. Raymond CB, Wazny LD: Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis. Am J Health Syst Pharm; 2008 Aug 1;65(15):1419-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cinacalcet, a calcimimetic agent that increases the sensitivity of the calcium-sensing receptor on the parathyroid gland to calcium, is believed to decrease serum parathyroid hormone levels and stabilize calcium and phosphate concentrations.

  • Genetic Alliance. consumer health - Calciphylaxis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SODIUM THIOSULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Health Syst Pharm. 2010 Jan 1;67(1):8
  • (PMID = 18653812.001).
  • [ISSN] 1535-2900
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Naphthalenes; 0 / Thiosulfates; 1K860WSG25 / Cinacalcet Hydrochloride; HX1032V43M / sodium thiosulfate
  •  go-up   go-down


78. Sebag F, Palazzo FF, Harding J, Sierra M, Ippolito G, Henry JF: Endoscopic lateral approach thyroid lobectomy: safe evolution from endoscopic parathyroidectomy. World J Surg; 2006 May;30(5):802-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 38 patients, the superior parathyroid gland was identified in 36 and the inferior parathyroid gland in 33.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2003 Oct;138(10):1140-3 [14557134.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1043-7 [12045859.001]
  • [Cites] Langenbecks Arch Surg. 2005 Apr;390(2):134-40 [15609056.001]
  • [Cites] Surgery. 2003 Dec;134(6):849-57 [14668714.001]
  • [Cites] Thyroid. 2002 Aug;12(8):703-6 [12225638.001]
  • [Cites] Surgery. 2002 Dec;132(6):1070-3; discussion 1073-4 [12490857.001]
  • [Cites] J Am Coll Surg. 2004 Aug;199(2):243-8 [15275880.001]
  • [Cites] Surg Clin North Am. 2004 Jun;84(3):717-34 [15145230.001]
  • [Cites] Surg Endosc. 2004 Aug;18(8):1208-10 [15457379.001]
  • [Cites] World J Surg. 2004 Dec;28(12 ):1239-47 [15517485.001]
  • [Cites] Asian J Surg. 2003 Apr;26(2):82-5 [12732491.001]
  • [Cites] Langenbecks Arch Surg. 2005 Jun;390(3):230-5 [15785957.001]
  • [Cites] J Gastrointest Surg. 2005 Mar;9(3):381-8 [15749601.001]
  • [Cites] Br J Surg. 2005 Jun;92(6):719-23 [15856491.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1219-23 [15517493.001]
  • (PMID = 16680595.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Goto S, Komaba H, Fukagawa M: Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention. NDT Plus; 2008 Aug;1(Suppl 3):iii2-iii8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention.
  • Secondary hyperparathyroidism is characterised by excessive secretion of parathyroid hormone and parathyroid hyperplasia, resulting in both skeletal and extraskeletal consequences.
  • Recent basic and clinical studies have brought considerable advances in our understanding of the pathophysiology of parathyroid hyperplasia and have also provided practical therapeutic approaches, especially with regard to indications for parathyroid intervention.
  • Patients with nodular hyperplasia should undergo parathyroid intervention including percutaneous ethanol injection therapy (PEIT).
  • Selective PEIT of the parathyroid gland is an effective approach in which the enlarged parathyroid gland with nodular hyperplasia is 'selectively' destroyed by ethanol injection, and other glands with diffuse hyperplasia are then managed by medical therapy.
  • With a more focused attention to applying parathyroid intervention, we can expect significant improvement in the management of secondary hyperparathyroidism in dialysis patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25983967.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4421132
  • [Keywords] NOTNLM ; chronic kidney disease / fibroblast growth factor 23 / parathyroid hyperplasia / parathyroid intervention / secondary hyperparathyroidism
  •  go-up   go-down


80. Yeh CT, Lin YP, Yang WC, Yang AH, Lai MY, Lin CC: Rapid recurrence of hyperparathyroidism from both nodularly hyperplastic autograft at forearm and residual tissues at neck after parathyroidectomy in a hemodialysis patient with calciphylaxis. Am J Med Sci; 2006 May;331(5):284-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Residual parathyroid gland in the retrothyroid region was found later.
  • Rapidly recurrent HPT originating from both the residual parathyroid tissues and the enlarged autograft within such short time after parathyroidectomy is rare in the literature.
  • The multinodular hyperplasia pattern of the parathyroid gland may be a major factor for such rapid recurrence.
  • In addition to good control of calcium and phosphate, regular follow-up of parathyroid hormone level and imaging studies of not only autografted gland at the forearm but also possibly residual parathyroid tissues at the neck are important for monitoring recurrence in maintenance hemodialysis patients after parathyroidectomy with forearm autograft, especially in those with pathologic type of nodular hyperplasia and calciphylaxis.
  • [MeSH-major] Calciphylaxis / complications. Hyperparathyroidism, Secondary / diagnosis. Kidney Failure, Chronic / therapy. Parathyroid Glands / pathology. Parathyroidectomy
  • [MeSH-minor] Adult. Calcium / blood. Diabetes Mellitus, Type 2 / complications. Female. Forearm / pathology. Humans. Hyperplasia / complications. Neck / pathology. Parathyroid Hormone / blood. Phosphates / blood. Recurrence. Renal Dialysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Calciphylaxis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702801.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 0 / Phosphates; SY7Q814VUP / Calcium
  •  go-up   go-down


81. Chen CM, Chu P, Huang GS, Wang SJ, Wu SS: Spontaneous rupture of the patellar and contralateral quadriceps tendons associated with secondary hyperparathyroidism in a patient receiving long-term dialysis. J Formos Med Assoc; 2006 Nov;105(11):941-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a 30-year-old man with uremia who underwent subtotal parathyroidectomy because of secondary hyperparathyroidism with very high serum parathyroid hormone (PTH) level (1940.4 pg/mL).
  • Early surgical repair, control of secondary hyperparathyroidism, early use of vitamin D analogs, and total parathyroidectomy with or without autotransplantation of part of the parathyroid gland, can treat and prevent tendon rupture or re-rupture with satisfactory results.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17098696.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


82. Koenig K, Kleerekoper M: How common are functional incidentalomas of the parathyroid gland? Nat Clin Pract Endocrinol Metab; 2006 Jun;2(6):316-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How common are functional incidentalomas of the parathyroid gland?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16932308.001).
  • [ISSN] 1745-8366
  • [Journal-full-title] Nature clinical practice. Endocrinology & metabolism
  • [ISO-abbreviation] Nat Clin Pract Endocrinol Metab
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


83. Li Z, Liu CP, Shi L, Huang T: [Operation for differentiated thyroid cancer: a experience of 546 cases]. Zhonghua Wai Ke Za Zhi; 2008 Mar 1;46(5):375-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence rate of single lateral recurrent laryngeal nerve injury was 1.1% (6 cases), parathyroid gland partly injury was 0.4% (2 cases), superior laryngeal nerve injury was 0.7% (4 cases), bleeding was 0.6% (3 cases) and esophagus injury after operation was 0.2% (1 case).
  • It is necessary to excise cervical lymph node when the tumor's diameter exceeds 1 cm.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18785536.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


84. Saidak Z, Mentaverri R, Brown EM: The role of the calcium-sensing receptor in the development and progression of cancer. Endocr Rev; 2009 Apr;30(2):178-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apart from its primary role in Ca(2+)(o) homeostasis, the CaR may be involved in phenomena that allow for the development of many types of benign or malignant tumors, from parathyroid adenomas to breast, prostate, and colon cancers.
  • In contrast, colon and parathyroid cancers often present with reduced or absent CaR expression, and activation of this receptor decreases cell proliferation, suggesting a role for the CaR as a tumor suppressor gene.
  • Thus, the CaR may play an important role in the development of many types of neoplasia.
  • Herein, we review the role of the CaR in various benign and malignant tumors in further detail, describing its contribution to parathyroid tumors, breast, prostate, and colon cancers, and we evaluate how pharmacological manipulations of this receptor may be of interest for the treatment of certain cancers in the future.
  • [MeSH-minor] Animals. Cell Proliferation. Disease Progression. Humans. Models, Biological. Neoplasm Metastasis. Parathyroid Glands / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19237714.001).
  • [ISSN] 1945-7189
  • [Journal-full-title] Endocrine reviews
  • [ISO-abbreviation] Endocr. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Calcium-Sensing
  • [Number-of-references] 235
  •  go-up   go-down


85. Graham A, Okabe M, Quinlan R: The role of the endoderm in the development and evolution of the pharyngeal arches. J Anat; 2005 Nov;207(5):479-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In particular, we focus on the emergence of the parathyroid gland, which we have recently shown to be the result of the internalization of the gills.
  • [MeSH-minor] Animals. Gene Expression Regulation, Developmental. Humans. Mouth / embryology. Parathyroid Glands / embryology. Pharynx / embryology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mech Dev. 2001 Mar;101(1-2):233-6 [11231082.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17716-9 [15591343.001]
  • [Cites] Mech Dev. 2001 May;103(1-2):141-3 [11335122.001]
  • [Cites] Development. 2001 Aug;128(15):3017-27 [11532923.001]
  • [Cites] J Morphol. 1951 Jan;88(1):49-92 [24539719.001]
  • [Cites] Curr Biol. 1999 Dec 16-30;9(24):1481-4 [10607595.001]
  • [Cites] Development. 2000 Apr;127(8):1553-62 [10725232.001]
  • [Cites] Nature. 2000 Jul 13;406(6792):199-203 [10910362.001]
  • [Cites] Dev Biol. 2000 Sep 15;225(2):339-56 [10985854.001]
  • [Cites] Development. 2000 Dec;127(24):5355-65 [11076757.001]
  • [Cites] Development. 2000 Dec;127(24):5367-78 [11076758.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):97-101 [11242049.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):286-91 [11242110.001]
  • [Cites] Cell. 2001 Feb 23;104(4):619-29 [11239417.001]
  • [Cites] Development. 2001 Aug;128(16):3081-94 [11688558.001]
  • [Cites] Development. 2002 Feb;129(4):1061-73 [11861488.001]
  • [Cites] Development. 2002 Sep;129(18):4301-13 [12183382.001]
  • [Cites] Dev Dyn. 2002 Sep;225(1):54-60 [12203720.001]
  • [Cites] Development. 2002 Oct;129(19):4457-68 [12223404.001]
  • [Cites] Dev Biol. 2003 Dec 15;264(2):522-36 [14651935.001]
  • [Cites] Development. 2004 Feb;131(3):593-9 [14711875.001]
  • [Cites] Differentiation. 1974 Jun;2(3):151-68 [4442672.001]
  • [Cites] Dev Biol. 1983 Mar;96(1):144-65 [6825950.001]
  • [Cites] Dev Suppl. 1991;1:187-96 [1683802.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1317-31 [7903600.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1333-49 [7903601.001]
  • [Cites] Development. 1995 Jul;121(7):1989-2003 [7635047.001]
  • [Cites] Curr Biol. 1996 Apr 1;6(4):417-26 [8723346.001]
  • [Cites] Development. 1996 Oct;122(10):3229-42 [8898235.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12364-9 [9770492.001]
  • [Cites] Development. 1999 Feb;126(5):895-902 [9927591.001]
  • [Cites] Nat Genet. 1999 Apr;21(4):444-8 [10192400.001]
  • [Cites] Nat Cell Biol. 2001 May;3(5):E117-23 [11331897.001]
  • (PMID = 16313389.001).
  • [ISSN] 0021-8782
  • [Journal-full-title] Journal of anatomy
  • [ISO-abbreviation] J. Anat.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 35
  • [Other-IDs] NLM/ PMC1571564
  •  go-up   go-down


86. Akimoto T, Saito O, Muto S, Hasegawa T, Nokubi M, Numata A, Ando Y, Sohara Y, Saito K, Kusano E: A case of thoracic hemorrhage due to ectopic parathyroid hyperplasia with chronic renal failure. Am J Kidney Dis; 2005 Jun;45(6):e109-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of thoracic hemorrhage due to ectopic parathyroid hyperplasia with chronic renal failure.
  • We report a case of secondary hyperparathyroidism in a 53-year-old man who had thoracic hemorrhage originating from an ectopic thymic parathyroid gland tumor.
  • He was on long-term hemodialysis treatment and had persistent secondary hyperparathyroidism caused by 3 swollen parathyroid glands around the thyroid gland and a mediastinal ectopic parathyroid gland tumor.
  • Parathyroidectomy and removal of the mediastinal tumor were planned.
  • Thoracoscopy confirmed the presence of a mediastinal tumor lesion that was bleeding into the thoracic cavity.
  • The tumor was resected using thoracoscopic surgery, and ectopic thymic parathyroid gland hyperplasia associated with hemorrhage was pathologically diagnosed.
  • A postoperative diagnostic chest computed tomographic scan and technetium 99m 2-methoxyisobutyl isonitrile scintigraphy showed successful removal of the ectopic parathyroid gland tumor.
  • We consider that hemorrhage from the ectopic parathyroid gland tumor resulted in thoracic bleeding.
  • To our knowledge, this is the first case report of secondary hyperparathyroidism with thoracic hemorrhage originating from an ectopic mediastinal parathyroid gland.
  • [MeSH-major] Adenoma / complications. Choristoma / complications. Hemorrhage / etiology. Hyperparathyroidism, Secondary / etiology. Kidney Failure, Chronic / complications. Lymphatic Diseases / etiology. Mediastinal Diseases / etiology. Parathyroid Glands. Parathyroid Neoplasms / complications. Thymus Gland / pathology

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15957122.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


87. Walker Harris V, Jan De Beur S: Postoperative hypoparathyroidism: medical and surgical therapeutic options. Thyroid; 2009 Sep;19(9):967-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hypoparathyroidism occurs when the parathyroid glands, through lack of secretion of or resistance to parathyroid hormone (PTH), are unable to maintain calcium homeostasis.
  • Drawbacks to conventional therapy, including narrow therapeutic window and propensity for hypercalciuria and hypercalcemia, have prompted investigation into alternatives, namely PTH replacement and parathyroid gland autotransplantation.
  • CONCLUSION: Long-term supplementation with vitamin D or its analogues and oral calcium is the mainstay of management of postoperative hypoparathyroidism; however, PTH replacement strategies with either PTH or parathyroid gland autotransplantation are emerging as alternative strategies to avoid the complications of conventional therapy.
  • [MeSH-major] Calcium / therapeutic use. Hypoparathyroidism / drug therapy. Parathyroid Hormone / therapeutic use. Postoperative Complications / therapy. Vitamin D / therapeutic use
  • [MeSH-minor] Humans. Hypocalcemia / etiology. Parathyroid Glands / surgery. Parathyroid Glands / transplantation. Transplantation, Autologous

  • Genetic Alliance. consumer health - Hypoparathyroidism.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19731978.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 1406-16-2 / Vitamin D; SY7Q814VUP / Calcium
  •  go-up   go-down


88. Sugino K, Ito K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, Yano Y, Ito K: Minimally invasive surgery for primary hyperparathyroidism with or without intraoperative parathyroid hormone monitoring. Endocr J; 2010;57(11):953-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive surgery for primary hyperparathyroidism with or without intraoperative parathyroid hormone monitoring.
  • We analyzed the utility of intraoperative parathyroid hormone (IOPTH) monitoring in minimally invasive surgery for primary hyperparathyroidism (pHPT).
  • A group who underwent surgery without IOPTH monitoring (Group 1; n=87), and a group who underwent surgery with IOPTH monitoring (Group 2; n=80), in which IOPTH was measured at 5, 10, 15 minutes after excision of the abnormal parathyroid gland.
  • An enlarged parathyroid gland that was consistent with the results of a preoperative imaging study was found in 84 patients (96.6%).
  • [MeSH-major] Hyperparathyroidism, Primary / blood. Hyperparathyroidism, Primary / surgery. Parathyroid Hormone / blood. Parathyroidectomy / methods

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20823623.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Parathyroid Hormone
  •  go-up   go-down


89. Low TH, Clark J, Gao K, Eris J, Shannon K, O'Brien C: Outcome of parathyroidectomy for patients with renal disease and hyperparathyroidism: predictors for recurrent hyperparathyroidism. ANZ J Surg; 2009 May;79(5):378-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among them, 5-20% require further re-exploration and excision of parathyroid tissue because of recurrent disease.
  • On re-exploration, persistent hyperplastic parathyroid tissue was located at the site of partially excised parathyroid gland (64%), autotransplanted parathyroid tissue (9%), anterior mediastinum (18%) and intrathyroidal parathyroid (9%).

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19566521.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


90. Hagforsen E, Michaëlsson K, Lundgren E, Olofsson H, Petersson A, Lagumdzija A, Hedstrand H, Michaëlsson G: Women with palmoplantar pustulosis have disturbed calcium homeostasis and a high prevalence of diabetes mellitus and psychiatric disorders: a case-control study. Acta Derm Venereol; 2005;85(3):225-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nearly 50% of palmoplantar pustulosis sera produce immunofluorescence of the palmar papillary endothelium from healthy subjects, but also of the endothelium of normal parathyroid gland.
  • With a case-control design the levels of calcium and parathyroid hormone in serum were measured in 60 women with palmoplantar pustulosis and 154 randomly selected population-based control women.
  • Mean age-adjusted serum calcium was increased in the patients compared with the controls (2.43 vs 2.36 mmol/l; p<0.0001), whereas the parathyroid hormone concentration was suppressed (23.2 vs 31.1 ng/l; p<0.0001).
  • The plasma levels of parathyroid hormone-related protein were normal in patients but there was a strong expression of this protein in the acrosyringium both in palmoplantar pustulosis and control skin.
  • [MeSH-major] Calcium / blood. Diabetes Mellitus. Mental Disorders / complications. Parathyroid Hormone-Related Protein / metabolism. Psoriasis / metabolism


91. Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D: Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int; 2005 Feb;67(2):467-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.
  • BACKGROUND: Secondary hyperparathyroidism (HPT) in chronic kidney disease (CKD) is a physiologic response to kidney failure characterized by elevated serum parathyroid hormone (PTH) levels and parathyroid gland enlargement.
  • Calcimimetic agents acting through allosteric modification of the calcium-sensing receptor (CaR) can attenuate parathyroid hyperplasia in rats with secondary HPT.
  • The present study explores the effects of the calcimimetic cinacalcet HCl on parathyroid hyperplasia, apoptosis, and PTH secretion in a rat model of secondary HPT.
  • After dosing, hyperplasia was determined using parathyroid weight and proliferating cell nuclear antigen (PCNA) immunochemistry.
  • RESULTS: Administration of cinacalcet HCl (5 or 10 mg/kg) significantly reduced the number of PCNA-positive cells and decreased parathyroid weight compared with vehicle-treated 5/6 nephrectomized rats.
  • CONCLUSION: The results confirm previous work demonstrating that calcimimetic agents attenuate the progression of parathyroid hyperplasia in subtotally nephrectomized rats, extending earlier observations to now include cinacalcet HCl.
  • These results support a role for the CaR in regulating parathyroid cell proliferation.
  • [MeSH-major] Hyperparathyroidism, Secondary / drug therapy. Naphthalenes / therapeutic use. Parathyroid Glands / drug effects
  • [MeSH-minor] Animals. Apoptosis / drug effects. Calcium / blood. Cinacalcet Hydrochloride. Hyperplasia. Male. Parathyroid Hormone / blood. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15673294.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Naphthalenes; 0 / Parathyroid Hormone; 1K860WSG25 / Cinacalcet Hydrochloride; SY7Q814VUP / Calcium
  •  go-up   go-down


92. Oztürk M, Ustek D, Akbas F, Kösem M, Abaci N, Alagöl F, Oztürk G, Kotan C: The presence of erythropoietin receptor in parathyroid cells. J Endocrinol Invest; 2007 Dec;30(11):RC35-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of erythropoietin receptor in parathyroid cells.
  • CONTEXT: Effects of erythropoietin on parathyroid cell function has not been studied before.
  • OBJECTIVE: We aimed to demonstrate whether erythropoietin receptor present in parathyroid cells.
  • DESIGN: The specimens of normal parathyroid gland, parathyroid adenoma and hyperplasia were retrieved from our pathology archives.
  • Its density was higher in normal parathyroid, followed by parathyroid adenoma and hyperplasia.
  • CONCLUSION: Erythropoietin receptor is present in normal parathyroid, parathyroid adenoma, and hyperplasia.
  • [MeSH-major] Adenoma / metabolism. Parathyroid Glands / metabolism. Parathyroid Neoplasms / metabolism. Receptors, Erythropoietin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Nephrol. 2004 Jan;15 Suppl 1:S21-4 [14684666.001]
  • [Cites] Adv Clin Path. 1997 Oct;1(4):275-280 [10352490.001]
  • [Cites] Nephrol Dial Transplant. 2002;17 Suppl 5:28-31 [12091604.001]
  • [Cites] Ann Clin Lab Sci. 2003 Fall;33(4):411-22 [14584755.001]
  • [Cites] J Pak Med Assoc. 1996 Jun;46(6):128-31 [8991369.001]
  • [Cites] Oncologist. 2004;9 Suppl 5:18-30 [15591419.001]
  • [Cites] Acta Endocrinol (Copenh). 1992 Aug;127(2):138-41 [1529660.001]
  • (PMID = 18250608.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Receptors, Erythropoietin; 11096-26-7 / Erythropoietin
  •  go-up   go-down


93. Mizobuchi M, Ritter CS, Krits I, Slatopolsky E, Sicard G, Brown AJ: Calcium-sensing receptor expression is regulated by glial cells missing-2 in human parathyroid cells. J Bone Miner Res; 2009 Jul;24(7):1173-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcium-sensing receptor expression is regulated by glial cells missing-2 in human parathyroid cells.
  • Glial cells missing-2 (Gcm2) is the key regulating transcription factor for parathyroid gland development.
  • The continued expression of high levels of Gcm2 in mature parathyroid glands suggests that it is required for maintenance of parathyroid cell differentiation.
  • The role of Gcm2 in parathyroid cell physiology, however, has not been fully studied.
  • In this study, we examined the effects of Gcm2 silencing on cultured human parathyroid cells.
  • Collagenase-dispersed human parathyroid cells from patients with chronic kidney disease were placed in monolayer cultures and infected with lentivirus expressing shRNA for human Gcm2.
  • These results indicate that one function of Gcm2 is to maintain high levels of CaR expression in parathyroid cells.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 1993 Jun;132(6):2639-44 [8389284.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):50062-8 [12397062.001]
  • [Cites] J Biol Chem. 1995 May 26;270(21):12919-25 [7759551.001]
  • [Cites] Cell. 1995 Sep 22;82(6):1013-23 [7553843.001]
  • [Cites] Cell. 1995 Sep 22;82(6):1025-36 [7553844.001]
  • [Cites] Development. 1996 Jan;122(1):131-9 [8565824.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14912-6 [8962155.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4739-44 [9114061.001]
  • [Cites] J Biol Chem. 1998 Feb 27;273(9):5253-9 [9478982.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12364-9 [9770492.001]
  • [Cites] J Biol Chem. 1999 Nov 5;274(45):32279-86 [10542267.001]
  • [Cites] Mech Dev. 2000 Mar 1;91(1-2):197-208 [10704844.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7553-7 [10713061.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(7):2466-74 [10713170.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):248-50 [10888863.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):311-4 [10888880.001]
  • [Cites] Nature. 2000 Jul 13;406(6792):199-203 [10910362.001]
  • [Cites] J Bone Miner Res. 2004 Mar;19(3):491-8 [15040838.001]
  • [Cites] EMBO J. 1998 Nov 2;17(21):6316-26 [9799239.001]
  • [Cites] Kidney Int. 1999 Apr;55(4):1284-92 [10200992.001]
  • [Cites] Surgery. 2004 Dec;136(6):1261-6 [15657585.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):2487-92 [15728199.001]
  • [Cites] Dev Biol. 2007 May 1;305(1):333-46 [17382312.001]
  • [Cites] J Mol Endocrinol. 2008 Jan;40(1):13-21 [18096993.001]
  • [Cites] Hum Mutat. 2009 Jan;30(1):85-92 [18712808.001]
  • [Cites] J Clin Invest. 2001 Oct;108(8):1215-20 [11602629.001]
  • [Cites] Development. 2002 Jul;129(14):3295-309 [12091301.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):30337-50 [12036954.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Oct;57(4):501-5 [12354132.001]
  • [Cites] Endocrinology. 1995 Apr;136(4):1419-25 [7895652.001]
  • (PMID = 19257819.001).
  • [ISSN] 1523-4681
  • [Journal-full-title] Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • [ISO-abbreviation] J. Bone Miner. Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK020579; United States / NIDDK NIH HHS / DK / P60 DK020579; United States / NIDDK NIH HHS / DK / 5P30DK07933; United States / NIDDK NIH HHS / DK / DK-20579
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GCM2 protein, human; 0 / Nuclear Proteins; 0 / Parathyroid Hormone; 0 / Proliferating Cell Nuclear Antigen; 0 / Receptors, Calcitriol; 0 / Receptors, Calcium-Sensing; 0 / Transcription Factors; EC 1.14.- / Steroid Hydroxylases; EC 1.14.- / vitamin D 1-alpha hydroxylase
  • [Other-IDs] NLM/ PMC2697623
  •  go-up   go-down


94. Ichii M, Ishimura E, Okuno S, Chou H, Kato Y, Tsuboniwa N, Nagasue K, Maekawa K, Yamakawa T, Inaba M, Nishizawa Y: Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism. Nephron Clin Pract; 2010;115(3):c195-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism.
  • BACKGROUND/AIM: Cinacalcet, an allosteric modulator of the calcium-sensing receptor, effectively reduces serum parathyroid hormone (PTH).
  • It was examined whether a regression of parathyroid glands in hemodialysis patients with secondary hyperparathyroidism was induced by cinacalcet treatment.
  • METHODS: Ultrasonography of the parathyroid glands was performed to examine the changes in the parathyroid gland volumes after cinacalcet treatment in 58 patients.
  • The total volumes of the parathyroid glands were significantly decreased 6 months after cinacalcet treatment (942 +/- 747 vs. 708 +/- 550 mm(3), p < 0.0005).
  • There was a significant positive correlation between the parathyroid gland volumes at the start of cinacalcet treatment and the volume reduction in parathyroid glands (r = 0.716, p < 0.0001).
  • Of the 58 patients, the total parathyroid gland volume was decreased in 42 patients and increased in 16 although the doses of cinacalcet, phosphate binders or vitamin D were not significantly different.
  • CONCLUSION: Cinacalcet treatment in patients with secondary hyperparathyroidism significantly reduced the total parathyroid gland volume in a short 6-month period.
  • [MeSH-major] Hyperparathyroidism, Secondary / drug therapy. Hyperparathyroidism, Secondary / etiology. Kidney Failure, Chronic / drug therapy. Kidney Failure, Chronic / pathology. Naphthalenes / therapeutic use. Parathyroid Glands / drug effects. Parathyroid Glands / pathology. Renal Dialysis

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20413997.001).
  • [ISSN] 1660-2110
  • [Journal-full-title] Nephron. Clinical practice
  • [ISO-abbreviation] Nephron Clin Pract
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Naphthalenes; 1K860WSG25 / Cinacalcet Hydrochloride
  •  go-up   go-down


95. Dugonjić S, Ajdinović B, Cerović S, Janković Z: Validity of dual tracer 99mTc-tetrofosmin and 99mTc-pertechnetate subtraction parathyroid scintigraphy in patients with primary and secondary hyperparathyroidism. Vojnosanit Pregl; 2009 Dec;66(12):949-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validity of dual tracer 99mTc-tetrofosmin and 99mTc-pertechnetate subtraction parathyroid scintigraphy in patients with primary and secondary hyperparathyroidism.
  • BACKGROUND/AIM: Primary hyperparathyroidism (pHPT) is an endocrine disease with the third highest incidence of all endocrine disorders after diabetes mellitus and hyperthyroidism. pHPT is typically caused by a solitary parathyroid adenoma, less frequently by multiple parathyroid gland disease (MGD) and rarely by parathyroid carcinoma.
  • The aim of this study was to estimate sensitivity of dual tracer 99mTc-tetrofosmin and 99mTc-pertechnetate subtraction scintigraphy in detection of abnormal parathyroid glands in patients with pHPT and sHPT confirmed by histopathology.
  • METHODS: In 46 patients, (77 abnormal parathyroid glands), 30 with pHPT and 16 with sHPT parathyroid scintigraphy was done preoperatively.
  • All the patients had histopathological confirmation of diagnosis.
  • Abnormal parathyroid glands weighted from 0.1 to 7 g.
  • In the patients with sHPT scintigraphy detected 30 of 47 abnormal parathyroid glands (sensitivity 64%).
  • An overall sensitivity of scintigraphy per gland, for pHPT and sHPT in detecting 58 of 77 abnormal parathyroid glands was 75%.
  • CONCLUSION: An abnormal scintigraphic result per patient was found in 44 patients (sensitivity 96%) and 58 of 77 abnormal parathyroid glands were detected (sensitivity 750/0).
  • A high sensitivity of dual tracer subtraction 99mTc-tetrofosmin/99mTc-pertechnetate parathyroid scintigraphy in detecting abnormal parathyroid glands in primary and secondary hyperparathyroidism was achieved.

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20095513.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane; A0730CX801 / Sodium Pertechnetate Tc 99m
  •  go-up   go-down


96. Nishida H, Ishibashi M, Hiromatsu Y, Kaida H, Baba K, Miyake I, Ikedo H, Kato S, Fukami K, Iida S, Okuda S: Comparison of histological findings and parathyroid scintigraphy in hemodialysis patients with secondary hyperparathyroid glands. Endocr J; 2005 Apr;52(2):223-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of histological findings and parathyroid scintigraphy in hemodialysis patients with secondary hyperparathyroid glands.
  • To determine the usefulness of parathyroid scintigraphy in histological estimation for secondary hyperparathyroidism (2HPT) using Tc-99m sestamibi or Tc-99m tetrofosmin.
  • Tc-99m sestamibi (MIBI) and Tc-99m tetrofosmin (Tetro) parathyroid imaging following double-phase study, magnetic resonance imaging (MRI), and ultrasound were performed on 14 patients with 2HPT.
  • The uptake of two tracers in parathyroid areas was compared with the histopathologic findings.
  • Forty-nine parathyroid glands were surgically explored and histologically proven to be hyperplastic.
  • MIBI and Tetro parathyroid imagings detected 34 and 35 parathyroid glands, respectively.
  • Tc-99m MIBI or Tc-99m Tetro parathyroid scintigraphy therefore may be used clinically to distinguish N-type from D-type parathyroid gland hyperplasia.
  • [MeSH-major] Hyperparathyroidism, Secondary / pathology. Hyperparathyroidism, Secondary / radionuclide imaging. Parathyroid Glands / pathology. Parathyroid Glands / radionuclide imaging. Renal Dialysis

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863952.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


97. Tanaka M, Itoh K, Matsushita K, Matsushita K, Fukagawa M: Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism. Nephron Clin Pract; 2006;102(1):c1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
  • METHODS: The study population comprised 10 hemodialysis patients (6 males and 4 females, mean age; 51.5 +/- 13.5 years, mean HD period 13.7 +/- 3.5 years), with high intact-PTH level (>400 pg/ml) and 1 or 2 enlarged parathyroid glands detected by power Doppler ultrasonography.
  • The effect of combination therapy was monitored by measuring intact-PTH, serum Ca and P, bone metabolic markers, parathyroid gland volume and bone mineral density, prior to and at 6 and 12 months after PEIT.
  • RESULTS: Successful control of intact-PTH, bone metabolic markers and parathyroid gland volume was achieved using the combination therapy.
  • This combination therapy results in suppression of PTH secretion, regression of parathyroid hyperplasia and the control of CaxP product, which may prevent calcific uremic arteriolopathy in dialysis patients.
  • [MeSH-minor] Adult. Alkaline Phosphatase / blood. Bone Density. Calcium / blood. Comorbidity. Drug Therapy, Combination. Female. Humans. Injections, Intralesional. Injections, Intravenous. Kidney Failure, Chronic / epidemiology. Kidney Failure, Chronic / therapy. Male. Middle Aged. Parathyroid Hormone / blood. Phosphorus / blood

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • Hazardous Substances Data Bank. ETHANOL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 S. Karger AG, Basel.
  • (PMID = 16166800.001).
  • [ISSN] 1660-2110
  • [Journal-full-title] Nephron. Clinical practice
  • [ISO-abbreviation] Nephron Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Parathyroid Hormone; 103909-75-7 / maxacalcitol; 27YLU75U4W / Phosphorus; 3K9958V90M / Ethanol; EC 3.1.3.1 / Alkaline Phosphatase; FXC9231JVH / Calcitriol; SY7Q814VUP / Calcium
  •  go-up   go-down


98. Kao HL, Chang WC, Lee CH, Lee HS, Huang GS: Missed brown tumors in a young adult with decreased bone density. South Med J; 2010 Apr;103(4):371-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brown tumors, a benign osteolytic process, are most commonly caused by hyperparathyroidism.
  • Differentiation between the two lesions is dependent upon evaluation of serum biochemistry including serum calcium, phosphorous, and intact parathyroid hormone (I-PTH) levels.
  • Based on the radiographic findings and biochemistry results in a young adult patient, brown tumor was suspected and subsequently definitively diagnosed.
  • [MeSH-major] Bone Neoplasms / diagnosis. Giant Cell Tumor of Bone / diagnosis. Hyperparathyroidism, Primary / diagnosis. Osteitis Fibrosa Cystica / diagnosis. Parathyroid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Bone Diseases, Metabolic / etiology. Diagnosis, Differential. Diagnostic Errors. Fibula / pathology. Humans. Hypercalcemia / etiology. Male. Osteolysis / diagnosis. Osteolysis / pathology. Parathyroid Hormone / blood. Parathyroidectomy. Tibia / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20224492.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone
  •  go-up   go-down


99. Périé S, Fessi H, Tassart M, Younsi N, Poli I, St Guily JL, Talbot JN: Usefulness of combination of high-resolution ultrasonography and dual-phase dual-isotope iodine 123/technetium Tc 99m sestamibi scintigraphy for the preoperative localization of hyperplastic parathyroid glands in renal hyperparathyroidism. Am J Kidney Dis; 2005 Feb;45(2):344-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of combination of high-resolution ultrasonography and dual-phase dual-isotope iodine 123/technetium Tc 99m sestamibi scintigraphy for the preoperative localization of hyperplastic parathyroid glands in renal hyperparathyroidism.
  • BACKGROUND: The usefulness of both dual-phase dual-isotope iodine 123 ( 123 I)/technetium Tc 99m ( 99m Tc) sestamibi scintigraphy and ultrasonography for the detection of hyperplastic parathyroid glands secondary to renal hyperparathyroidism is rarely addressed; most studies focus on primary hyperparathyroidism.
  • Results of both examinations, independently scored, were correlated with surgical and histopathologic findings for each hyperplastic parathyroid gland localization.
  • RESULTS: All parathyroid glands except 1 were found during primary surgery consisting of a subtotal parathyroidectomy (success rate, 99%).
  • The missed gland was removed successfully 1 month later.
  • Mean weight of totally removed parathyroid glands was 633 mg.
  • Ultrasonography detected 75% of hyperplastic parathyroid glands; dual-phase 123 I/ 99m Tc sestamibi scintigraphy, 66%; and a combination of both, 88%.
  • Most missed glands at scintigraphy corresponded to superior glands, whereas false-negative results at ultrasonography correlated with low gland weight.
  • CONCLUSION: Combined ultrasonography and 123 I/ 99m Tc sestamibi scintigraphy should be considered for routine use to localize hyperplastic parathyroid glands in patients with renal hyperparathyroidism undergoing surgery.
  • In our experience, this proved very helpful in achieving a high surgical success rate in patients with renal hyperparathyroidism, especially when the surgeon visualizes the parathyroid glands at ultrasonography.
  • [MeSH-major] Hyperparathyroidism / radionuclide imaging. Hyperparathyroidism / ultrasonography. Iodine Radioisotopes. Kidney Failure, Chronic / radionuclide imaging. Kidney Failure, Chronic / ultrasonography. Parathyroid Glands / radionuclide imaging. Parathyroid Glands / ultrasonography. Parathyroidectomy / methods. Preoperative Care / methods. Technetium Tc 99m Sestamibi

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15685513.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


100. Ak I, Acikalin MF: Hyperparathyroidism with a functioning parathyroid cyst. Clin Nucl Med; 2007 Sep;32(9):713-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperparathyroidism with a functioning parathyroid cyst.
  • A rare case of primary hyperparathyroidism with a functioning parathyroid cyst in whom Tc-99m MIBI scintigraphy failed to detect a parathyroid tumor is presented.
  • A 62-year-old woman with primary hyperparathyroidism was referred for Tc-99m MIBI imaging to investigate a parathyroid adenoma.
  • Plasma levels of intact parathyroid hormone were elevated to 2250 pg/mL.
  • Neck ultrasonography revealed a cystic lesion measured 30 x 42 x 35 mm on the right inferior side of the thyroid gland.
  • Pathologic diagnosis revealed a benign parathyroid cyst.
  • Her postoperative course was uneventful and plasma levels of intact parathyroid hormone normalized after operation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710026.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement